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COMMENTS
TAKE OFF YOUR GENES AND LET THE
DOCTOR HAVE A LOOK: WHY THE MAYO
AND MYRIAD DECISIONS HAVE
INVALIDATED METHOD CLAIMS FOR
GENETIC DIAGNOSTIC TESTING
CHRISTOPHER BERGIN*
Ass’n for Molecular Pathology v. U.S. Patent & Trade Office sent
shockwaves through the legal community, when the U.S. District Court for the
Southern District of New York rejected a series of patents held by Myriad
Genetics, Inc. The court invalidated all of Myriad’s compositional patents for
human genes and its method patents for diagnosing genetic predispositions to
breast cancer. While commentators have discussed the ethical implications of
allowing patent rights to human genes in great detail, the Court’s ruling on
Myriad’s method claims went by comparatively unnoticed.
The ability to test a patient’s genetic profile for predisposition to cancer and
other diseases is an incredible achievement in the field of personalized
medicine. Whether these tests deserve patent protection is a hotly debated issue
that involves weighing the interests of both incentivizing research and making
these tests available to the general public. This Comment analyzes the legal
framework established by the Supreme Court and U.S. Court of Appeals for the
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Candidate, May 2014, American University Washington College of Law; B.S. Biology, 2011,
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Jonas Anderson for his constant guidance, support, and encouragement through the
Comment process. Additionally, I would like to thank the entire American University
Law Review staff, who put a significant amount of time and energy into this piece.
Any mistakes are my own. Finally, I would like to thank my family for their
unconditional love and unwavering support throughout my entire law school
experience. Mom and Dad, thank you in particular for supplying me with my own
genetic material.
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Federal Circuit to decide patent eligibility for genetic diagnostic tests. It
concludes that, while the world was spellbound by the ethical quandary of
compositional claims on human genes, the recent Supreme Court and Federal
Circuit decisions have surreptitiously eliminated genetic diagnostic tests as
patentable subject matter under § 101 of the United States Patent Act.
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“We are on the leading edge of a true revolution in medicine, one
that promises to transform the traditional ‘one size fits all’ approach
into a much more powerful strategy that considers each individual as
unique and as having special characteristics that should guide an
approach to staying healthy.”1
INTRODUCTION
On March 3, 1986, the U.S. Department of Energy announced the
Human Genome Project: an unparalleled endeavor to decode the
entire human genome and one day develop “new diagnostic,
preventative and therapeutic tools.”2 Nearly thirty years later,
humanity has finally begun to harvest the fruits of this mammoth
endeavor.3 New technology, made possible by genetic research,
allows doctors to use a patient’s unique genetic profile to prevent,

1. Tiana Leia Russell, Unlocking the Genome: The Legal Case Against Genetic
Diagnostic Patents, 16 MARQ. INTELL. PROP. L. REV. 81, 81 (2012) (quoting FRANCIS S.
COLLINS, THE LANGUAGE OF LIFE: DNA AND THE REVOLUTION IN PERSONALIZED
MEDICINE, at xxiii-xxiv (2010)).
2. OFFICE OF HEALTH & ENVTL RESEARCH, U.S. DEP’T OF ENERGY, SEQUENCING THE
HUMAN GENOME: SUMMARY REPORT OF THE SANTA FE WORKSHOP 1 (1986) [hereinafter
SUMMARY REPORT], available at http://web.ornl.gov/sci/techresources/Human_
Genome/publicat/1986santafereport.pdf; see also Robert Kanigel, The Genome Project,
N.Y. TIMES (Dec. 13, 1987), http://www.nytimes.com/1987/12/13/magazine/thegenome-project.html?pagewanted=all&src=pm (describing the Human Genome
Project as “the biggest, costliest, most provocative biomedical research project in
history, and the United States must embark on it immediately”).
3. See Russell, supra note 1, at 82 (“Although personalized medicine remains in
its early stages, its potential to improve patients’ lives cannot be overstated.”); see also
Birgit Verbeure, Patent Pooling for Gene-Based Diagnostic Testing, in GENE PATENTS AND
COLLABORATIVE LICENSING MODELS 3, 15 (Geertrui Van Overwalle ed., 2009)
(explaining that currently, over a “thousand genetic diseases can be diagnosed
through available tests”).
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diagnose, and treat disease.4 As research efforts continue, this
practice—known as “personalized medicine”5—continues to
promise cheaper, more effective healthcare and incredible
diagnostic capability.6
Despite the benefits personalized medicine has already produced,
the field remains in its infancy.7 Unfortunately, courts have struggled
with encouraging the growth of this industry while simultaneously
ensuring equitable access to its benefits.8 This tension between
encouraging innovation and maintaining accessibility—which mirrors
the central conflict of patent law itself9—has resulted in a heated
debate as to whether human genes and genetic diagnostic tests ought
to receive patent protection.10 Supporters of patent protection for
genes and genetic tests argue that, without protection, researchers
will no longer be incentivized to invest in personalized medical
research.11 Opponents respond that patent monopolies impede
access and have a chilling effect on cooperative research efforts.12

4. Russell, supra note 1, at 82 (explaining that with advances in genetic
diagnostic methods, doctors are able to use an individual’s unique genetic code to
personalize treatments).
5. Genetics Home Reference, NATIONAL INST. OF HEALTH, http://ghr.nlm.nih.gov
/glossary=personalizedmedicine (last updated June 24, 2013) (defining
“personalized medicine” as “us[ing] an individual’s genetic profile to guide decisions
made in regard to the prevention, diagnosis, and treatment of disease”).
6. Russell, supra note 1, at 82 (“‘[M]ost of the promise offered by the
sequencing of the human genome still lies ahead.’” (quoting COLLINS, supra note 1,
at 3)).
7. Id.
8. Id. at 83 (describing whether genes and genetic tests deserve patent
protection as a “hotly debated issue”); see also Stephen H. Schilling, DNA as Patentable
Subject Matter and a Narrow Framework for Addressing the Perceived Problems Caused by Gene
Patents, 61 DUKE L.J. 731, 732 (2011) (highlighting the arguments of those who
object to gene patenting, such as the ethical implications of restricting access to
genetic tests or the negative impact of gene patents on foundational research).
9. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1305
(2012) (concluding that patent protection is a “two-edged sword” that provides both
incentives but also obstacles to creation and invention).
10. See Russell, supra note 1, at 82 (“As our understanding of the linkages
between genetic mutations and diseases has grown, so has a heated debate over
whether patents on genes are deserving of patent protection.”).
11. See, e.g., Schilling, supra note 8, at 772 (arguing that precluding patent
protection for isolated DNA sequences would “unravel sectors of the biotechnology
industry,” due to decreased investment in response to the lack of a guarantee of
market exclusivity).
12. See e.g., Russell, supra note 1, at 83 (listing the policy arguments against gene
patents including the “chilling effect” on research); Sean MacKenzie, Note,
Recognizing the Building Blocks of Life as Products of Nature: Association for Molecular
Pathology’s Rightful Exclusion of Genetic Information from Patentable Subject Matter, 32
WHITTIER L. REV. 367, 393 (2011) (arguing that property rights on products of
nature, such as genes, preempt research that could advance the cause of
personalized medicine and thus frustrate the very purpose of the patent system).
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In 2011, this conflict came to a head in Ass’n for Molecular Pathology
v. U.S. Patent & Trademark Office13 (Myriad I). Myriad Genetics, Inc.
(Myriad), a genetic researcher, held patents on two genes associated
with a high incidence of breast and ovarian cancer as well as patents
for genetic diagnostic tests, which identified a predisposition to these
cancers in a patient.14 On an initial remand from the Supreme
Court, the U.S. Court of Appeals for the Federal Circuit held that
(1) isolated genetic sequences remained eligible for patent
protection,15 and (2) Myriad’s diagnostic method patents were not
eligible for patent protection.16 The Supreme Court vacated and
remanded the case for further consideration17 in light of its
holding in Mayo Collaborative Services v. Prometheus Laboratories, Inc. 18
(Mayo), which held that simple, naturally occurring correlations
were unpatentable.19
On remand again in 2012, the Federal Circuit’s decision in Ass’n for
Molecular Pathology v. Myriad Genetics, Inc.20 (Myriad II) remained
nearly identical to its decision in Myriad I. The Federal Circuit
upheld Myriad’s compositional patent claims on isolated genes,21 and
rejected Myriad’s genetic diagnostic patents.22 This time, however,
the court’s reasoning was buttressed by the Supreme Court’s logic in
Mayo.23 The court’s holding in Myriad II on compositional patents
13. 653 F.3d 1329 (Fed. Cir. 2011), vacated, 132 S. Ct. 1794 (2012) (mem.),
remanded to 689 F.3d 1303 (Fed. Cir. 2012), aff’d in part, rev’d in part on other grounds,
133 S. Ct. 2107 (2013).
14. See id. at 1334–35 (describing the specific DNA sequences and diagnostic
methods claimed).
15. See id. at 1354 (noting that such compositional patents had been granted by
the U.S. Patent and Trade Office (USPTO) for the last thirty years and that changes
to such a longstanding practice should come from Congress).
16. See id. at 1357 (concluding that Myriad’s claims failed to satisfy the machineor-transformation test because they did not include any transformative steps).
17. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 (2012)
(mem.).
18. 132 S. Ct. 1289 (2012).
19. See id. at 1302 (explaining that Prometheus’s method is tied up in the
statistical relationship between metabolite levels and levels of appropriate medication
and suggesting a patent for Prometheus’s method would preempt the total use of
this correlation); see also infra notes 121–132 and accompanying text (providing an
overview of the Mayo analysis).
20. 689 F.3d 1303 (Fed. Cir. 2012), aff’d in part, rev’d in part on other grounds, 133
S. Ct. 2107 (2013).
21. Id. at 1333. But see id. at 1343 (Bryson, J., concurring in part and dissenting
in part) (“If I were deciding this case on a blank canvas, I might conclude that an
isolated DNA sequence that includes most or all of a gene is not patentable subject
matter.”).
22. See id. at 1335 (majority opinion) (“Myriad’s claimed methods of comparing
or analyzing nucleotide sequences are only directed to the abstract mental process of
comparing two nucleotide sequences.”).
23. Id. (explaining that the method claims in Myriad II were actually weaker than
those in Mayo because they lacked any kind of “Mayo-like step of determining,”
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garnered considerable media attention and sparked much
controversy.24 However, while the world questioned the wisdom of
patenting genes themselves, the Federal Circuit’s holding on Myriad’s
genetic diagnostic tests may have surreptitiously sounded the death
knell for genetic diagnostic patents altogether.
This Comment argues that, when viewed in conjunction with the
Supreme Court’s holding in Mayo, Myriad II categorically invalidated
genetic diagnostic method patents because any diagnostic test is an
exploitation of a simple correlation between the presence of a disease
allele and the likelihood for developing that disease. Part I of this
Comment provides an overview of the current patent legal landscape
as well as the method patents at issue. Part II contends that the
Supreme Court’s decision in Mayo combined with the Federal
Circuit’s holding in Myriad II—along with other medical patent
cases—creates a three-part test for diagnostic and therapeutic
method claims. Part II also looks at patents that were granted by the
U.S. Patent and Trademark Office (USPTO) before and after the
Myriad II decision, and applies this three-part test to investigate those
patents’ validity. This Comment concludes that due to these recent
decisions, patent law can no longer adequately protect genetic
diagnostic methods.
I.

SECTION 101 AND THE THRESHOLD TEST FOR PATENTABILITY

The U.S. Constitution empowers Congress to “promote the
Progress of Science and useful Arts, by securing for limited Times to
Authors and Inventors the exclusive Right to their respective Writings
which required researchers to measure a physical change); see also infra notes 132–
133 and accompanying text.
24. See, e.g., Katherine Booth, Isolated DNA Patents: Incentivizing Medical Research or
Selling Human Identity?: Association for Molecular Pathology v. U.S. Patent and
Trademark Office, 40 J.L. MED. & ETHICS 413, 416 (2012) (“There are strong moral
and philosophical arguments against isolated DNA patents.”); Schilling, supra note 8,
at 772 (referring to such objections to compositional DNA claims as “overreactions
that would do more harm than good”). These controversial compositional claims
seem to have eclipsed the Court’s ruling on genetic diagnostic tests. See, e.g., Daniel
Fisher, D.C. Court Upholds Myriad Breast-Cancer Patents, Snubbing Supreme Court, FORBES
(Aug. 16 2012), http://www.forbes.com/sites/danielfisher/2012/08/16/d-c-courtupholds-myriad-breast-cancer-patents-snubbing-supreme-court/2 (discussing the
Myriad decision but focusing on the compositional claims); Jonathan Stempel, Myriad
Wins Gene Patent Ruling from US Appeals Court, REUTERS (Aug. 16, 2012, 4:23 PM),
http://www.reuters.com/article/2012/08/16/us-myriad-patent-idUSBRE87F12K20120816
(dedicating only one sentence to Myriad’s method claims). Recently, the Supreme
Court has ruled on the admissibility of compositional gene patents, thus ending this
portion of the debate—at least temporarily. See Ass’n for Molecular Pathology v.
Myriad Genetics, Inc. (Myriad III), 133 S. Ct. 2107, 2118–19 (2013) (holding that,
although isolated gene fragments are unpatentable, manmade cDNA may receive
patent protection).
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and Discoveries.”25 This enables Congress to grant inventors the
absolute right to exclude others from making, using, or selling their
inventions.26 These exclusionary rights are conferred through
patents, which are granted by the USPTO.27 Although Congress has
broad authority to grant patents to inventors, the Constitution forbids
granting any patent that hinders innovation or fails to promote the
scientific welfare of the United States.28 Thus, the provisions of the
United States Patent Act—specifically 35 U.S.C. §§ 101, 102, 103, and
112—place limits on patentability and attempt to ensure that only
patents that encourage innovation are granted.29
Section 101 of the Patent Act, referred to as the “threshold test” for
patentability, explicitly limits patent protection to any “process,
machine, manufacture, or composition of matter.”30 The Supreme
Court has read § 101 to implicitly exclude any “laws of nature, natural
phenomena and abstract ideas” from patent protection.31 These
principles were not created through human ingenuity but are
naturally occurring and therefore, “free to all men and reserved
exclusively to none.”32 Allowing inventors the right to monopolize
such laws of nature would result in enormous market power, which
would tend to stifle innovation rather than encourage it.33

25. U.S. CONST. art. I, § 8, cl. 8.
26. 35 U.S.C. § 271(a) (2006).
27. Id. § 2(a)(1).
28. U.S. CONST. art. I, § 8, cl. 8.; Allen v. Ideal Prod., Inc., 300 F. Supp. 349, 351
(W.D. Pa. 1969) (“The very power of Congress to grant a patent is limited and
delineated by the purpose proclaimed in the constitutional grant itself. . . . ‘To
promote the Progress of Science and the useful Arts’ . . . .” (quoting Automatic Radio
Mfg, Co. v. Hazletine Research, 339 U.S. 827, 836–37 (1950))).
29. See 35 U.S.C. §§ 101–03, 112 (requiring that patents are only given to
inventions that are useful, novel, nonobvious, and described in detail). See generally
Mayo Collaborative Servs. v. Prometheus Labs., Inc. 132 S. Ct. 1289, 1303–04 (2012)
(describing the different statutory hurdles that prevent frivolous patents).
30. 35 U.S.C. § 101.
31. Diamond v. Diehr, 450 U.S. 175, 185 (1981); see also Mayo, 132 S. Ct. at 1293
(explaining that one could not patent a newly discovered mineral or a mathematical
formula such as E = mc2).
32. Diehr, 450 U.S. at 185 (quoting Diamond v. Chakrabarty, 447 U.S. 303, 309
(1980)).
33. MacKenzie, supra note 12, at 374–75 (describing why courts deny patent
protection to “fundamental truths” or “principles of nature”). A good example of
the Court’s reasoning for these exceptions can be found in O’Reilly v. Moorse, 56 U.S.
(15 How.) 62 (1853). In 1837 Samuel F.B. Morse sought a patent for the telegraph
and stated in his claim that he “[did] not propose to limit [himself] to the specific
machinery or parts of machinery described in the forgoing specification and claims;
the essence of [his] invention being . . . electro-magnetism.” Id. at 112. The
Supreme Court held that an inventor could not patent electro-magnetism, a law of
nature. Id. at 120. Such broad patent protection would inhibit future inventors from
making more efficient, or creative uses of electro-magnetism. Id. at 120–21.
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A. The Difficulty of Method Claims: Benson, Flook, and Diehr
Applying the exceptions of § 101 can be very difficult when
assessing the patentability of process claims, also known as “method
claims.”34 The three cases discussed in this section establish the
Court’s framework for determining the patentability of method
claims. Taken together, Benson, Flook, and Diehr confirm the Court’s
reluctance to allow patents on claims that preempt natural law and
foreshadow the difficulty in determining patentability for evaluating
novelty in a method claim.
In 1972, in Gottschalk v. Benson,35 the Supreme Court attempted to
draw a line between “a[n] idea itself,” and a “useful structure created
with the aid of knowledge of scientific truth” for a method claim.36 In
that case, an inventor attempted to patent an algorithm that
converted binary-coded decimal numerals into pure binary code.37
The Court held that this method claim was too abstract to be
considered a patentable invention.38 The Court’s reasoning rested
on the fact that the inventor applied mathematical principles that
could not be used except in connection with a computer.39 Thus, the
inventor’s patent on the computer algorithm would preempt the
mathematical formula and, in practical effect, would be a patent on
the mathematical principle itself.40
Six years later, in Parker v. Flook,41 the Supreme Court rejected
another computer algorithm, which, it claimed, preempted an entire
mathematical concept.42 In Flook, the inventor sought to obtain a
patent on an alarm system claiming a method comprising of (1)
determining the value of a variable, (2) using that variable to
calculate a new alarm limit, and (3) determining the new alarm
34. Russell, supra note 1, at 86 (“[T]he fundamental principles exception
can be a difficult standard to apply particularly when assessing the patentability
of process claims.”).
35. 409 U.S. 63 (1972).
36. Id. at 67 (alteration in original).
37. See id. at 66–67 (describing exactly how the method, called the BCD system,
worked, which simply “varie[d] the ordinary arithmetic steps a human would use”).
38. See id. at 68 (“Here the ‘process’ claim is so abstract and sweeping as to cover
both known and unknown uses of the BCD to pure binary conversion.”).
39. See id. at 71–72 (summarizing the court’s reasoning that a mathematical
formula is not patentable).
40. Id.; see also Russell, supra note 1, at 89–90 (explaining that this
rationale—namely, that an invention which entirely preempts a natural law is
unpatentable—is a fundamental principle of determining the patentability of a
method claim).
41. 437 U.S. 584 (1978).
42. See id. at 594–95 (stressing the fact that a claim which merely restates a
mathematical formula cannot be patented, even if the formula is used for a specific
purpose, such as in this case (citing In re Richman, 563 F.2d 1026, 1030 (1977))).
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limit.43 There, the inventor attempted to escape the logic of Benson
by claiming that the “post-solution” activity of adjusting the alarm
limit after the calculation prevented the method from preempting
the entire mathematic principle within the patent.44 The Supreme
Court disagreed, explaining that “[t]he notion that post-solution
activity, no matter how conventional or obvious in itself, can
transform an unpatentable principle into a patentable process exalts
form over substance.”45 Thus, the Court eliminated the possibility of
circumventing the rule against patenting an abstract idea by merely
attaching the abstract idea to a specific technological environment,
which would entirely pre-empt its use.46
In 1981, in Diamond v. Diehr47 the Supreme Court upheld a method
patent on a computer algorithm for the first time.48 In this case the
inventors sought patent protection for a method of molding rubber
into cured precision products using a mathematical formula and a
computer to complete many steps of the process.49 The Court found
that the patent in this case did not preempt an entire mathematical
formula, but instead claimed an industrial process for the creation of
a consumer product.50 The Court held that a process claim reciting a
fundamental principle of nature could be allowed patent protection;
however, “an inquiry must be made into whether the claim is seeking
patent protection for that formula in the abstract.”51
Thus, after Diehr the key inquiry was whether the process sought to
patent a formula in the abstract or whether the process went beyond
a recitation of some abstract principle. Together, these three cases
suggest that, to be patentable, a method claim cannot completely
preempt the natural law upon which it is based.52

43. See id. at 586. The invention in Flook was a method of setting an alarm limit
for a catalytic conversion process. Id. at 585. During a catalytic conversion process
temperature, pressure, and flow rates fluctuate. Id. These rates must be carefully
monitored to ensure that they remain within normal parameters. Id. An alarm limit
is a predetermined unsafe threshold. Id. Whenever a temperature, pressure, or flow
rate exceeds an alarm limit an alarm is triggered, which signals the presence of an
abnormal condition. Id.
44. Id. at 590.
45. Id.
46. See Russell, supra note 1, at 90 (noting that, under the Court’s reasoning in
Flook, if a claim does not disclose another inventive concept, apart from a
fundamental principle, natural law, or correlation, it is unpatentable under § 101).
47. 450 U.S. 175 (1981).
48. Id. at 193.
49. Id. at 178–79.
50. Id. at 191.
51. Id.
52. Russell, supra note 1, at 89–90 (explaining the importance of preemption in
the Supreme Court’s reasoning in its patent decisions).
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B. The Machine-or-Transformation Test: A Bright-Line Clue
Eventually, the Federal Circuit examined the Supreme Court’s
reasoning in Diehr, Flook, and Benson, and tried to extrapolate a
bright-line rule. This “definitive test” would greatly simplify the
determination of whether a method was appropriate subject matter
under § 101. The Federal Circuit sat en banc in In re Bilski53 to decide
whether a method for hedging risk qualified as patentable subject
The court set forth the “machine-ormatter under § 101.54
transformation” test as the “correct test” for validity under § 101.55
Under this test an inventor can demonstrate that his process claim
satisfies § 101 by “showing that his claim is tied to a particular
machine, or by showing that his claim transforms an article.”56
The inventors conceded that their method of hedging risk was not
tied to a machine or machinated process; however, they claimed their
method “transform[ed] the relationships” between various players in
the industry.57
The Federal Circuit disagreed, stating that
manipulations of legal obligations, relationships, and business risks
are abstractions and not physical substances.58 As such, the method
was held unpatentable.59
The Supreme Court granted certiorari and upheld the judgment60
but rejected the notion that the “machine-or-transformation” test was
determinative for patentability.61 The Supreme Court did, however,

53. 545 F.3d 943 (Fed. Cir. 2008) (en banc), aff’d sub nom. on other grounds, Bilski
v. Kappos, 130 S. Ct. 3218 (2010), remanded to 659 F.3d 1057 (Fed. Cir. 2011). The
Federal Circuit described the § 101 inquiry as “hardly straightforward” and discussed
the “limited usefulness” of Supreme Court precedent, id. at 954, until the
establishment of the machine-or-transformation test by the Supreme Court. See
infra notes 60–64 and accompanying text (discussing the subsequent Supreme
Court decision).
54. In re Bilski, 545 F.3d at 949–50.
55. See id. at 955 (describing the Supreme Court’s definitive “machine-ortransformation” test that determines whether a process claim is designed to cover
only a specific application of a fundamental principle rather than the abstract
principle itself); see also id. at 961 (listing rejected tests such as the physical steps
test and physical limitations test in favor of the machine-or-transformation test
for a § 101 inquiry).
56. Id. at 961. See generally Angela D. Follet, Note, The Problem with Bilski: Medical
Diagnostic Patent Claims Reveal Weaknesses in a Narrow Subject Matter Test, 7 U. ST.
THOMAS L.J. 229, 240–41 (2009) (providing an overview of the rationale behind the
machine-or-transformation test: a claim must be limited to particular applications of
a fundamental principle).
57. In re Bilski, 545 F.3d at 64.
58. Id. at 963.
59. Id. at 966.
60. See Bilski v. Kappos, 130 S. Ct. 3218, 3231 (2010) (holding the petitioner’s
process claim as invalid under § 101 because their claims attempted to patent the use
of an abstract idea to a particular field).
61. Id. at 3226.
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reason that the test was an “important and useful clue” and
The Court
investigative tool for determining patentability.62
reiterated that the correct standard for patentability was inquiring as
to whether a method amounted to laws of nature or abstract ideas.63
Nevertheless, the Supreme Court failed to offer any additional
guidance other than referring to its previous logic in Diehr, Flook
and Benson.64
C. Method Patents in a Biomedical Context: Non-Genetic Diagnostic
Method Patents
Diagnostic method patents have been at the center of a
considerable amount of controversy and have raised significant equity
and ethical concerns.65 The Supreme Court and the Federal Circuit
have had two major opportunities to tackle these challenging ethical
issues: Laboratory Corp. of America Holdings v. Metabolite Laboratories,
Inc.66 and Classen Immunotherapies, Inc. v. Biogen IDEC.67 These cases,
discussed below, set forth a basic framework for understanding how
courts examine diagnostic method patents.
Metabolite Laboratories
In Metabolite Laboratories, Inc. v. Laboratory Corp. of America Holdings,68
the Federal Circuit upheld a patent that claimed a method for
Metabolite
detecting B vitamin deficiency in a patient.69
Laboratories’ method was composed of (1) assaying a body fluid for
an elevated level of a certain protein, homocystine, and (2)
correlating an elevated level of homocystine in body fluid with a B
vitamin deficiency.70 Laboratory Corporation of America challenged
this patent on multiple grounds; however, it did not challenge the
correlation as unpatentable subject matter under § 101 until it
1.

62. Id.
63. Id. at 3238–39.
64. Id. at 3235, 3238–39; see also Asher Hodes, Note, Diagnosing Patentable Subject
Matter, 26 BERKELEY TECH. L.J. 225, 228–29 (2011) (explaining that many
commentators have observed this lack of Supreme Court guidance).
65. See generally Hodes, supra note 64, at 229–30 (detailing examples of
controversial court decisions, and disputes dealing with diagnostic medical patents).
66. 548 U.S. 124 (2006) (per curiam) (dismissing the writ of certiorari as
improvidently granted).
67. 659 F.3d 1057 (Fed. Cir. 2011), cert. denied sub nom. GlaxoSmithKline v.
Classen Immunotherapies, Inc., 133 S. Ct. 973 (2013).
68. 370 F.3d 1354 (Fed. Cir. 2004), cert. dismissed per curiam, 548 U.S. 124 (2006).
69. Id. at 1358.
70. Id. at 1358–59.
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petitioned for certiorari to the Supreme Court.71 Although the Court
granted certiorari, it subsequently dismissed the writ as improvidently
granted.72 Justice Breyer dissented to the dismissal, joined by Justices
Stevens and Souter.73
Justice Breyer attacked Metabolite’s patent, stating that there was
little doubt that the correlation between the protein and the related
biological result was a natural phenomenon.74 He explained that
claim thirteen’s process simply instructed the user to “(1) obtain test
results and (2) think about them.”75 Justice Breyer argued that this
transformative step was irrelevant because it was not at the core of the
patent and, thus, could not have altered the patent’s overall subject
matter.76 However, despite the aggressive tone of his dissent, the
Federal Circuit has declined to follow Justice Breyer’s reasoning.77
Classen
In Classen Immunotherapies, Inc. v. Biogen IDEC,78 the U.S. District
Court for the District of Maryland held that a method of discovering
an optimal immunization schedule was only a simple correlation and,
thus, unpatentable subject matter under § 101.79 The claimed
2.

71. See Brief for the United States as Amicus Curiae at 16, Lab Corp., 548 U.S. 124
(No. 04-607), 2005 WL 3533248 (noting that no § 101 challenge was asserted nor did
any of the lower courts address the issue).
72. Lab. Corp., 548 U.S. at 125; see also Hodes, supra note 64, at 230 (suggesting
that certiorari was revoked due to the failure to raise the patentable subject matter
issue prior to its petition).
73. Lab. Corp., 548 U.S. at 125 (Breyer, J., dissenting).
74. See id. at 135 (adding “[t]hat is what the petitioner argues. It is what the
Solicitor General has told us. Indeed, it is close to what the respondents concede.”
(citation omitted)); see also id. at 137–38 (“[The claims] embody only the correlation
between homocystine and vitamin deficiency that the researchers uncovered.”).
75. Id. at 136.
76. See id. at 135, 137–38 (expounding that the steps involved in the process did
not embody much beyond a natural phenomenon); see also Hodes, supra note 64, at
230–31 (referencing Justice Breyer’s assertion that the “measuring step” needed to
measure the amino acids was immaterial for purposes of qualifying the method for
patentability under § 101).
77. See, e.g., Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347,
1356 n.2 (Fed. Cir. 2010) (explicitly declining to examine Justice Breyer’s reasoning
in Lab. Corp. because a dissent is not controlling law and Lab. Corp. involved claims
for a business method), rev’d, 132 S. Ct. 1289 (2012); see also Hodes, supra note 64, at
241 (predicting that a broad application of Justice Breyer’s standard would invalidate
all correlative diagnostic patents, including those in Prometheus and Myriad because it
would be impossible to draft a valid patent if courts presumed that claims preclude
all applications of the natural processes involved in an invention’s operation).
78. No. WDQ-04-2607, 2006 WL 6161856 (D. Md. Aug. 16, 2006), aff’d, 304 F.
App’x 866 (Fed. Cir. 2008), vacated, 130 S. Ct. 3541 (2010), remanded to 659 F.3d 1057
(Fed. Cir. 2011), cert. denied sub nom. GlaxoSmithKline v. Classen Immunotherapies,
Inc., 133 S. Ct. 973 (2013).
79. See id. at *5 (“[The] patents describe little more than an inquiry of the extent
of the proposed correlation between vaccines and chronic disorders. . . . [T]he
Court finds they are an attempt to patent an unpatentable natural phenomenon.”).
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process involved: (1) identifying two groups of mammals of the same
species, with Group A having been immunized according to
immunization schedule one, and Group B having been immunized
according to immunization schedule two; and (2) comparing the
effectiveness of the first and second immunization schedules.80 In
2008, the Federal Circuit affirmed the district court’s decision and
cited In re Bilski for support.81 Then, after rejecting the “machineor-transformation” test in Bilski,82 the Supreme Court granted
certiorari in Classen and—on the same day—remanded it to the
Federal Circuit.83
On remand, the Federal Circuit reversed its earlier decision and
held that Classen’s method of optimizing an immunization schedule
was patentable subject matter under § 101.84 The court relied upon
the key “immunization step” in moving this method from an abstract
idea into a valid method patent.85 The court suggested that this
immunization step was transformative for the purposes of the
“machine-or-transformation” test.86 Collectively, Classen, Metabolite,
Myriad, and Mayo set the framework for determining the future
patentability of medical diagnostic tests based on a patient’s
genetic material.87

80. Classen Immunotherapies, Inc. v. Biogen IDEC, 659 F.3d 1057, 1060 (Fed.
Cir. 2011), cert. denied sub nom. GlaxoSmithKline, 133 S. Ct. 973.
81. See Classen Immunotherapies, Inc. v. Biogen IDEC, 304 F. App’x 866, 867
(Fed. Cir. 2008) (explaining that the claims failed the “machine-or-transformation”
test (citing In re Bilski, 545 F.3d 943, 954 (Fed. Cir. 2008) (en banc)).
82. 130 S. Ct. 3218, 3226 (2010) (declining to recognize the “machine-ortransformation” test as determinative for purposes of determining what
constitutes a “process”).
83. Classen Immunotherapies, Inc. v. Biogen IDEC, 130 S. Ct. 3541, 3541 (2010),
remanded to 659 F.3d 1057 (Fed. Cir. 2011).
84. Classen, 659 F.3d at 1068.
85. See id. (arriving at its conclusion by looking at the invention as a whole,
including the scope asserted by the patentee); see also PerkinElmer, Inc. v. Intema
Ltd., 496 F. App’x 65, 71 n.2 (Fed. Cir. 2012) (denying the patentability of the claims
at issue because, unlike in Classen, there was no “further act” moving the recited
concepts to a specific application), cert. denied, No. 12-1372, 2013 WL 2155734 (Oct.
7, 2013).
86. See Classen, 659 F.3d at 1068 (describing the actual immunization of an
animal as a “transformative” step).
87. See John D. Lopinksi, Clash of the Titans: How the Prometheus, Myriad, and
Classen Cases Are Shifting the Sands, in THE IMPACT OF RECENT PATENT LAW CASES AND
DEVELOPMENTS 149, 150–51 2011) (arguing that the future of biotech patent law is
found within Myriad, Mayo, and Classen because these cases provide a rationale for
including a particular description in biotech patent applications in order to increase
the likelihood that a claim will be patentable under § 101). See generally Hodes, supra
note 64, at 230–34, 236–37 (detailing the various courts’ reasoning in these four
cases as the roadmap to understanding genetic diagnostic correlation methods as
patentable subject matter).
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D. The Stage Is Set for Method Patents: Understanding the Legal
Framework
As described above, case precedent leading up to the court’s
determination in Myriad occurred in three phases: (1) a concern for
preemption (Benson, Flook, and Diehr);88 (2) the machine-ortransformation test (Bilski);89 and (3) the Court’s attempt to
define the scope and boundaries of diagnostic methods (Classen
and Metabolite).90
In Benson, Flook, and Diehr, the Court’s decisions established that a
method patent cannot entirely preempt all uses of a law of nature;
and that meaningless “post-solution activity” would be irrelevant to
the issue of patentability.91 In Bilski, the Supreme Court rejected the
“machine-or-transformation” test as a definitive rule for patentability
under § 101 and instead insisted that the test was merely a useful
clue.92 Finally, in Classen and Metabolite, the Supreme Court and
Federal Circuit found the “machine-or-transformation” test useful in
determining the patentability for diagnostic procedures.93 Taken
together, these cases suggest that a transformation is only valid if it
occurs at the core of the patent and involves a novel step.94
With these cases, the Supreme Court and Federal Circuit provided
a legal foundation capable of addressing the problems posed by
diagnostic and genetic patents. The next Supreme Court cases, Mayo
and Myriad, expanded and solidified this framework.
E. Before Genetic Patents: A Brief Biology Primer
Before delving into an argument about the patentability of genetic
diagnostic tests, a brief introduction to molecular biology and
genetics is helpful. DNA is a chemical molecule composed of several

88. Supra note 52 and accompanying text.
89. Supra notes 60–63 and accompanying text.
90. See supra notes 78–86 and accompanying text (providing the facts of
Classen of an example of how the “machine-or-transformation” test influences the
court’s analysis).
91. See supra notes 41–45 and accompanying text.
92. See supra notes 60–64 and accompanying text (outlining the holding in Bilski
and emphasizing the rejection of the “machine-or-transformation” test as
determinative).
93. See supra text accompanying note 86 (describing the influence of the
“machine-or-transformation” test in Classen); see also PerkinElmer, Inc. v. Intema Ltd.,
496 F. App’x 65, 71 n.2 (Fed. Cir. 2012) (explaining that the immunization was a
“further step,” that moved the “abstract scientific principle to specific application”),
cert. denied, No. 12-1372, 2013 WL 2155734 (Oct. 7, 2013).
94. See supra notes 66–86 (describing Classen and Lab. Corp.); see also PerkinElmer,
496 F. App’x at 71 n.2 (explaining that the immunization was a “further act,” one
that moved the “abstract scientific principle to specific application”).
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subparts known as nucleotides.95 Genetic DNA is composed of four
different kinds of nucleotides: A, G, C, and T, which are chemically
bonded together in varying combinations.96 For example, a DNA
fragment may be:
G-A-C-G-A-C, G-G-T-G-G-C, or some other
combination of nucleotides.97 Full DNA chains involve thousands of
nucleotides strung together.98 A person’s cellular machinery can
read this sequence of nucleotides and recognize them as a subset of
smaller discrete units, known as genes.99
A gene, the basic unit of heredity, is a subpart of the genome; it is a
person’s sum total of DNA.100 A gene is a particular stretch of
nucleotides that usually encodes for one particular protein.101 Genes
are responsible for the inheritance of discrete traits such as sex, race,
and disease predisposition.102
For the most part, DNA is the same from person to person.103
Everyone shares almost the exact overall nucleotide sequence and,
therefore, the same genes.104 The normal version of a gene is known
as the “wild-type” gene.105 Occasionally, a person’s cellular machinery
makes a mistake and gives a person a new nucleotide sequence in a
particular gene.106 This event results in a mutated version of the same
gene.107 These mutations are heritable and some are correlated with
an increased risk of particular diseases.108
95. MacKenzie, supra note 12, at 371.
96. Id.
97. See id. (explaining that sequencing determines the arrangement of
nucleotides).
98. Russell, supra note 1, at 94.
99. See Schilling, supra note 8, at 734 (describing nucleotides as “spell[ing] out
biological messages” for the cell).
100. George Dandalides, The Patentability of Isolated DNA Sequences Deoxyribonucleic
Acid (DNA), 14 TUL. J. TECH. & INTELL. PROP. 283, 283 (2011).
101. See Schilling, supra note 8, at 734 n.14 (explaining that proteins are molecules
responsible for performing the majority of a cell’s functions, including directing
most of a cell’s chemical processes, generating movements, sensing signals, and
maintaining structures).
102. See Russell, supra note 1, at 94 (providing that genes contain exons, necessary
for the creation of proteins, and introns, which contain regulatory sequences that
affect a body’s rate of production of the protein encoded by a gene).
103. See Dandalides, supra note 100, at 284 (noting that although only less than
one percent of nucleotides within the genes vary slightly between individuals, these
variances cause the unique differences among individuals, ranging from skin and eye
color to variations presenting significant consequences to a person’s health).
104. Id.
105. See Russell, supra note 1, at 95 (explaining that “wild-type” genes do not have
any variations, but that when variations do occur, they occur at different magnitudes,
resulting in varying levels of health risks).
106. Id.
107. See id. (relaying that small scale mutations manifest as slight sequence
differences between the same genes in different individuals and large mutations can
include the addition or elimination of substantial chromosomal regions).
108. See id. (explaining that in some cases a certain mutation may make a disease
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DNA sequencing is a procedure that allows researchers to
determine the specific order of nucleotides within a DNA strand.109
When a “wild-type” gene is sequenced, the researcher knows the
ordinary combination of nucleotides for the “normal” version of the
gene.110 If doctors know the “wild-type” version of a gene, they can—
with relative ease—take a DNA sample from a patient and compare
the patient’s particular gene against the “wild-type” version of that
gene.111 If the two match, the patient has the normal “wild-type”
gene.112 If they differ, the patient has a mutated version of the
gene.113 If this particular mutation corresponds with a predisposition
to a disease condition, then the doctor can inform the patient, and
the two can begin to take preventative measures.114
F.

Considering Mayo and Myriad: The Emerging Rule of Genetic Patents

1. The three step-inquiry and Mayo: Naturally occurring correlations with
meaningless post or pre-solution activity are unpatentable under § 101
In Mayo, the Supreme Court considered two method patents held
by Prometheus Labs, which claimed methods for determining the
optimal level of medicine—6-Tgioguanine (“6-TG”)—to give to a
patient with Crohn’s Disease.115 If the concentration of 6-TG in the
bloodstream was too high, one could suffer from significant
complications and side effects.116 If the concentration of 6-TG was

condition all but certain). For example cystic fibrosis (CF), a disease affecting the
lungs, pancreas, and sweat glands, is actually caused by a genetic mutation, which is
passed down from parent to child. Kristine Barlow-Stewart, Fact Sheet # 33, Cystic
Fibrosis, CENTER FOR G ENETICS E DUC . 1 (Nov. 2012), http://www.genetics.edu.au
/Publications-and-Resources/Genetics-Fact-Sheets/FS33KBS.pdf.
See generally
Conditions: Cystic Fibrosis, G ENETICS H OME R EFERENCE , http://ghr.nlm.nih.gov
/condition/cystic-fibrosis (last updated August, 2012) (explaining, in detail, how
genetic mutations may cause or contribute to disease conditions, and how these
mutations are inherited).
109. Russell, supra note 1, at 95.
110. Id.
111. Id. at 95–96 (describing that this type of comparison can occur when
researchers attempt to locate genes tied to various conditions using linkage analysis).
112. Id. at 95.
113. Id.
114. Id. (emphasizing the usefulness and difficulty in locating a particular genetic
mutation tied to a specific disease condition).
115. See Mayo Collaborative Servs. v. Prometheus Labs., Inc. 132 S. Ct. 1289, 1295
(2012) (detailing the patent’s findings that distinct concentrations of 6-TG or 6-MMP
metabolite in a patient’s blood could indicate that the dosage was either too high or
too low to be effective).
116. See U.S. Patent No. 6,355,623 col.1 l.66 (filed Apr. 8, 1999) (“Complications
associated with [6-TG] drug treatment include allergic reactions, neoplasia,
opportunistic infections, hepatitis, bone marrow suppression, and pancreatitis.”),
invalidated by Mayo, 132 S. Ct. 1289.
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too low, the treatment would be ineffective.117 Prometheus had
found the therapeutic sweet spot and claimed a process for finding
the appropriate dose of 6-TG to give to a patient by: (1) giving 6-TG
to a patient with Crohn’s; (2) taking a blood sample from that patient
and determining the concentration of 6-TG in their bloodstream,
and (3) making a determination regarding a threshold concentration
level of 6-TG in the patient’s blood.118 If the level of 6-TG was above a
threshold concentration (400 picomoles per 8x108 red blood cells),
the patient would receive less 6-TG; if the level of 6-TG was below a
certain threshold concentration (230 picomoles per 8x108 red blood
cells), the patient would receive more 6-TG.119 This method relied
upon the natural relationship between the concentration of 6-TG in
the bloodstream and the likelihood of harmful side effects or
ineffectiveness.120 Before examining the patents, the Court cited
Benson, Flook, and Diehr, and explained that a process that
“preempt[s] the use of a natural law” could not be patented.121 The
question before the court then became whether the patent claims
added enough to the correlation statements to make the described
claims “patent-eligible” processes that applied natural laws.122
a. Mayo’s method patents: U.S. Patent No. 6,680,302 and U.S.
Patent No. 6,355,623
The two patents at issue in Mayo were the ‘302 Patent and the ‘623
Patent.123 Before beginning its analysis the Court warned that any
attempt to monopolize a law of nature would not be rewarded with a
patent.124 Then, the Court initiated its inquiry by separating out the
distinct steps of the methods at issue.125

117. Mayo, 132 S. Ct. at 1295.
118. See id. (labeling the steps as the “administering” step, the “determin[ation]”
step, and the “wherein” step).
119. Id. (quoting the ‘623 Patent). The same method could be accomplished by
measuring the level of 6-metyl-mercaptopurine (6-MMP) in the patient’s blood
stream after administering 6-TG. Id.
120. Id.
121. Id. at 1294; see also id. (asserting that the Court’s precedents forewarn against
determining patent eligibility too broadly or without careful examination as to
whether the patent contains an “inventive concept” as opposed to an insignificant
post-solution activity).
122. Id. at 1298.
123. Id. at 1295 (suggesting that the two patents were nearly identical; although,
the ‘302 Patent provided a more precise therapeutic range when measuring 6-MMP).
124. See id. at 1297 (analogizing to the Greek scholar Archimedes, and asserting
that “Archimedes [could not] have secured a patent for his famous principle of
flotation by claiming a process consisting of simply telling boat builders to refer to
that principle in order to determine whether an object will float”); see also Funk Bros.
Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948) (construing “law of nature”
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The Court looked at the “administering” step, which instructed a
doctor to dose a patient with 6-TG.126 The court noted that doctors
have been treating Crohn’s disease with 6-TG for many years, so this
step was merely an attempt “to limit the use of [a] formula to a
particular technological environment.”127 As such, it did not add
anything to the law of nature, which in this case, was the naturally
occurring correlation between levels of 6-TG in the blood and
harmful side effects for patients.128
Second, the court looked at the “wherein” step. For this patent,
the step simply described the relevant concentration thresholds for 6TG.129 The Court stated that this step merely informed a doctor
about a natural correlation and suggested that the doctor take this
correlation into consideration.130 The Court likened this step to a
situation where Einstein might simply explain his basic law to linear
accelerator operators and trust them to use it.131
Third, the Court looked at the final “determining” step, which
involved taking a blood sample and measuring the levels of 6-TG.132
The process of taking a blood sample and measuring metabolite
levels was considered commonplace by the scientific community, and
the court analogized this step to the “conventional or obvious
[pre/post] solution activity” in Bilski which was incapable of turning a
law of nature into a patentable process.133
After examining the steps of the patent separately and determining
that nothing new was being added to the law of nature—other than
conventional and widely used pre-solution activity—the Court

to include any phenomenon of nature, such as the heat of the sun, electricity, or the
qualities of metals or bacterium).
125. See Mayo, 132 S. Ct. at 1297–98 (separating the claims into three steps—an
“administering” step, a “determining” step, and a “wherein” step—to demonstrate
how these additional steps were insufficient to transform the nature of the claims
because they simply inform a targeted audience about the relevance of natural laws).
126. Id. at 1297.
127. Id. at 1291 (internal quotation marks omitted). The Court, however, insisted
that the “administering step,” although albeit a transformation, was irrelevant
because it simply helped pick out individuals who would be interested in applying
the law of nature. Id. at 1297; see also Douglas L. Rodgers, After Prometheus, are
Human Genes Patentable Subject Matter?, 11 Duke L. & Tech. Rev. 434, 454, 456–60
(2013) (arguing that, more than anything else, the steps of a method must include
an innovative step).
128. See Mayo, 132 S. Ct. at 1294 (proffering that an application of a law of nature to
a new and useful end may be patentable, but that such protection cannot be afforded
to a claim that merely recited a law of nature while adding the words “apply it”).
129. Id. at 1297.
130. Id.
131. Id.
132. Id. at 1297–98.
133. Id.
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considered the steps as a whole.134 Yet, even when considering the
three steps as a part of an ordered combination, the Court found that
nothing new was added to the law of nature.135 Thus, these patents
simply amounted to a set of instructions telling doctors to measure
the level of the relevant metabolite, use the relevant laws of nature to
calculate toxicity, and reassess use of the drug given the relevant law
of nature.136
In Mayo, the Court determined the method’s patentability by first
separating out the steps of the method to consider whether any of the
steps added anything to the law of nature that was not “wellunderstood, routine, conventional activity.”137 Next, the Court
considered the method as a whole to see if, as a system, the process
added anything to the law of nature.138 Prometheus asserted that its
process passed the “machine-or-transformation” test by (1)
transforming the human body when administering 6-TG, and (2) by
transforming the patient’s blood when analyzing the metabolites.139
Without much explanation, the Supreme Court immediately
dismissed the first transformation as “irrelevant.”140 Regarding the
second transformation, the Court gave only two brief justifications:
(1) the step could theoretically be satisfied without transforming the
blood “should science develop a totally different system for
determining metabolite levels,” and (2) the machine-ortransformation test was merely an important clue that did not trump
the Court’s initial inquiry into whether the patented process was
simply a law of nature.141

134. Id. at 1298.
135. Id.
136. See id. at 1299–1300 (emphasizing that these steps simply instructed doctors
to apply the law of nature in a particular way when treating their patients). It is
crucial to note that the Court was referring only to the steps surrounding the law of
nature as “well-understood, routine, conventional activity.” Id. at 1298. In contrast,
the law of nature itself had never before been discovered and was incredibly useful.
See id. at 1295 (noting that researchers’ discovery was a correlation between
“metabolite levels and likely harm or ineffectiveness” of 6-TG). Nevertheless, without
producing a novel, unconventional, or non-routine activity, Prometheus was unable
to obtain its patent. Id. at 1298.
137. Id. at 1298.
138. Id.
139. Id. at 1302.
140. Id. at 1302–03 (disagreeing with Prometheus’s position that the claimed
processes were patentable by asserting that the step could be accomplished without
transforming the blood).
141. Id. at 1303.
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b. Explanations for transformations: Help from Flook, Diehr, and
Metabolite
There are two potential explanations as to why transformations like
the ones alleged in Mayo are insufficient for patentability. First, the
transformation was routine and thus added nothing significant to the
method. Second, the transformation was not central to the method
claim. The Court in Mayo did not explicitly discuss either of these
reasons but, as outlined below, they are deduced from the Court’s
reasoning.
i.

The transformation was routine

The first reason for rejecting the Prometheus patent was that there
was nothing new about analyzing a patient’s blood after
administering a well-known and commonly used drug.142 These steps
could not add enough novelty to raise the method above a simple law
Although these transformations occurred, they
of nature.143
amounted to meaningless pre/post-solution activity.144
The difference between transformative steps and meaningless
pre/post-solution activity can be found by comparing Flook and Diehr.
In Flook, the presence of an alarm was not enough to raise an
algorithm based on a law of nature to patentability.145 The Court
simply considered the alarm to be a conventional and obvious postsolution activity.146 On the other hand, in Diehr an algorithm was
held patentable.147 There, the process was used to produce cured
synthetic rubber.148 The Diehr method resulted in a nonobvious and
useful product; thus, it was deemed to be an “industrial process.”149
The key to differentiating these cases is recognizing that the Diehr
method resulted in a useful and nonobvious product,150 whereas the
Flook method merely included a conventional and previously-available
142. See supra note 127 and accompanying text (noting that doctors have been
treating Crohn’s disease with 6-TG for many years).
143. See Mayo, 132 S. Ct. at 1297–98 (explaining that the drugs used for the
method had been used “long before anyone asserted [the] claims,” that the
“methods for determining metabolite levels were well known in the art,” and that
therefore, the additional steps were routine).
144. See id. at 1298 (explaining that the “determining” step is meaningless, wellunderstood post-solution activity).
145. See Parker v. Flook, 437 U.S. 584, 593–95 (1978) (explaining that the claims
could not be protected by a patent, not simply because the only novel feature of the
method was a mathematical formula, but because once the mathematical formula
was applied, the claims as a whole contained no patentable invention).
146. Id. at 591.
147. Diamond v. Diehr, 450 U.S. 175, 192–93 (1981).
148. Id. at 187.
149. Id. at 192.
150. Id. at 191–92.
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alarm.151 Applying this logic to Mayo potentially leads to the
conclusion that transformations are only significant for the purposes
of method claims if they themselves are unconventional and
nonobvious or result in a nonobvious product.152
Additional support for this theory is found in Justice Breyer’s
dissent from the denial of certiorari in Metabolite. There, Justice
Breyer explained that using an unpatented and well-understood
procedure for “transforming” blood samples during one step of a
patented method, although leading to a “useful, concrete, and
tangible result” should be considered irrelevant in determining
whether a patent is valid.153 This view, taken together with the
Supreme Court’s reasoning in Flook and Benson, indicates that a
transformation must involve or produce a novel or nonobvious
material to be relevant for the § 101 patentability analysis.
Recently, the Federal Circuit had an opportunity to expand on this
rationale in PerkinElmer, Inc. v. Intema Ltd.154 There, the Federal
Circuit examined a patented method of determining a fetus’s
chances of having Down Syndrome.155 The patent was comprised of
two steps: (1) measuring the levels of certain biological markers in the
blood, and (2) determining whether those levels indicated a
heightened risk of Down Syndrome.156 The Federal Circuit explained
151. Flook, 437 U.S. at 594–95; see also Gottschalk v. Benson, 409 U.S. 63, 70 (1972)
(explaining that processes “involving mechanical operations and producing a new
and useful result” are generally patentable (emphasis added) (quoting Expanded
Metal Co. v. Bradford, 214 U.S. 366, 385–86 (1909))).
152. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1292
(2012) (contrasting Diehr and Flook, both of which addressed processes using
mathematical formulas; and, explaining that in Diehr the additional steps of the
process integrated the equation into the process as a whole, transforming the process
into an inventive application of the formula, while in Flook the additional steps of the
process were not limited to a particular application).
153. See Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124, 136
(2006) (Breyer, J., dissenting) (emphasizing that it was illogical to interpret
whether it mattered that the test results themselves were obtained through an
unpatented procedure because many procedures could involve “the use of
empirical information obtained through an unpatented means that might have
involved transforming matter”).
154. 496 F. App’x 65, 71 (Fed. Cir. 2012) (construing the validity of a patent
disclosing specific screening methods meant to estimate the risk of fetal Down
Syndrome after the U.S. District Court for the District of Massachusetts held the
asserted claims unpatentable because they were anticipated and obvious, and
therefore granted summary judgment), cert. denied, No. 12-1372, 2013 WL 2155734
(Oct. 7, 2013).
155. See id. at 67 (acknowledging this test as beneficial compared to other tests
that carry a significant risk of miscarriage).
156. See id. at 66–67 (discussing the patent at issue and explaining that the key
difference between representative claims one and twenty was that in claim twenty
patients were screened into either “screen positive” or “screen negative” groups, with
only “screen negative” patients undergoing testing in the second trimester)).
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that the measuring step was an insufficient transformation to make
the claim patent-eligible because the available measurement
procedures were already known and, therefore, nothing more than
“conventional or obvious pre-solution activity.”157
ii. The transformation was not central to the method claims
Another explanation for the unpatentability of the transformations
in Mayo could be that the transformation was not central to the
method being claimed. Although the Supreme Court never explicitly
mentioned this reason in Mayo, Justice Breyer did explain that
measuring metabolite levels could theoretically be satisfied without
transforming the blood if science developed a new method for
making this determination that did not involve transforming the
blood.158 In other words, this step was not a crucial part of the
overall method.
Although the Supreme Court did not explicitly consider this step
in Mayo, courts generally have held that a transformation needs to be
central to the claims of the method to raise the method above the
§ 101 bar.159 For example, in Bilski, the Federal Circuit explained that
a transformation “must be central to the purpose of the claimed
process.”160 Although the Federal Circuit failed to elaborate on this
point, Justice Breyer’s dissent in Metabolite is again informative.
There, Justice Breyer argued that a step, that simply instructed a
person to measure products in a patient’s bloodstream, could not be
a valid transformation.161 Justice Breyer explained, “[w]hy should it
matter if the test results themselves were obtained through . . . the
transformation of blood? Claim 13 is indifferent to that fact, for it

157. Id. at 71 (internal quotation marks omitted).
158. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1303
(2012).
159. See, e.g., In re Bilski, 545 F.3d 943, 962 (Fed. Cir. 2008) (concluding that the
“machine-or-transformation test” is the sole test to determine patentability and
providing that if the claimed process transforms a particular article into a different
state or thing, it is patent-eligible), aff’d sub nom. on other grounds, Bilski v. Kappos, 130
S. Ct. 3218 (2010); SmartGene v. Advanced Biological Labs., SA 852 F. Supp. 2d 42,
62 (D.D.C. 2012) (explaining that one of the guidelines to determine if a claimed
process is patent eligible under the machine or transformation test is whether the
transformation is central to the process instead of mere manipulation of abstract
nonphysical objects or substances); Bancorp Servs., LLC v. Sun Life Assurance Co. of
Can., 771 F. Supp. 2d 1054, 1066 (E.D. Mo. 2011) (concluding that a claim was not
patentable because the claims did “not transform the raw data into anything other
than more data and are not representations of any physically existing objects”).
160. Bilski, 545 F.3d at 962.
161. See Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124, 125,
136–38 (2006) (Breyer, J., dissenting) (per curiam) (arguing that respondents’
described process was not a process for transforming blood or any other matter).
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tells the user to use any test at all.”162 Thus, if a transformation is
unnecessary for the central purpose of the patent, it should not be
considered when determining patentability. Additionally, careful
drafting that writes a natural law, correlation, or phenomenon into
the patent’s process does not elevate the process to patentability.163
Thus, the transformation in Metabolite was trivial to the patent; it did
not matter how the user measured the blood or whether that
measurement involved a transformation.164 Similarly, in Mayo, how
the user obtained 6-TG measurements from the patient, and whether
that step involved a transformation, was irrelevant to the purpose of
the patent.165
2.

Myriad: Genetic diagnostic tests are simple correlations at their core
a.

Genetic diagnostics and biology

As discussed above, DNA sequencing is a procedure that allows
researchers to determine the specific order of nucleotides within a
DNA strand.166 This technique allows researchers to determine
whether an individual has the normal (“wild type”) version of a gene
or a mutated version of a gene.167 If the individual has a mutated
gene, and this particular mutation corresponds with a predisposition
to a disease condition, then the doctor can inform the patient and
the two can begin to take preventative measures.168
Myriad held compositional patents on the “wild-type” and mutant
versions of two genes: BRCA1 and BRCA2.169 Mutant BRCA genes
correspond to a very high incidence of breast and ovarian cancers;170
thus, they are incredibly helpful in identifying a patient’s
162. Id. at 136.
163. Id. at 137.
164. See id. at 136 (suggesting that the administering step is unimportant in
determining patentability).
165. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1303
(2012) (concluding that the “administering” step is “irrelevant”); see also Bilski v.
Kappos, 130 S. Ct. 3218, 3227 (2010) (explaining that recent case law has deemed
the machine-or-transformation test not exhaustive; rather, it is merely a “clue to the
patentability” of a claimed process).
166. Myriad II, 689 F.3d 1303, 1311 (Fed. Cir. 2012), aff’d in part, rev’d in part on
other grounds, 133 S. Ct. 2107 (2013).
167. Id. at 1341 (Moore, J., concurring in part).
168. See, e.g., id. at 1314 (majority opinion) (describing the usefulness of results in
determining an appropriate course of cancer treatment).
169. See Myriad III, 133 S. Ct. at 2113. It is important to note that compositional
patents differ from method patents, where the claims are for a process rather than a
gene or molecule itself. See Myriad II, 689 F.3d at 1310 (describing Myriad’s method
claims as diagnostic methods focused on identifying specific mutations associated
with breast or ovarian cancer).
170. Myriad III, 133 S. Ct. at 2113.
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predisposition to cancer.171 Additionally, Myriad held that diagnostic
method patents, which attempted to claim the process of comparing
the “wild-type” BRCA genes to a patient’s specific BRCA genes to
determine whether a patient was predisposed to these cancers.172
This comparative process allows a doctor to take a DNA sample from
a patient, determine whether the patient has the BRCA mutant gene,
and thus identify patients with a higher likelihood of developing
breast and ovarian cancer.173 If a patient discovers that she carries a
mutated BRCA1 and BRCA2 gene, she could then take steps to
manage and treat her risk of cancer.174 The Federal Circuit initially
rejected these method patents.175 The Supreme Court then vacated
the Federal Circuit’s decision and remanded the case following its
decision in Mayo.176
b.

Comparing and analyzing methods: Myriad on remand

On remand, the Federal Circuit was instructed to consider Myriad
in light of the Supreme Court’s decision in Mayo.177 The Association
for Molecular Pathology brought an action against Myriad alleging
that fifteen claims from seven patents were ineligible subject
matter under § 101.178 Six of the challenged claims were method
claims.179 The Court separated these method claims into two

171. See, e.g., Consumers Have Few Negative Reactions to the Results of Genetic Testing for
Cancer Mutations, Study Shows, SCI. D AILY (Feb. 12, 2013), http://www.sciencedaily
.com/releases/2013/02/130212075428.htm (explaining that a small percentage of
breast cancers occur in women who have a genetic predisposition for the disease,
which is usually due to mutations in either the BRCA1 or BRCA2 gene).
172. See Myriad II, 689 F.3d at 1310, 1314 (describing how large sets of DNA
samples from families with inherited breast and ovarian cancers allowed Myriad to
correlate the occurrence of cancer in individual family members with the inheritance
of specific marker DNA sequences, which in turn facilitated Myriad’s diagnostic
testing services).
173. Id. at 1314.
174. See Russell, supra note 1, at 100 (noting a patient’s “range of options for
managing their risk of cancer, including increased surveillance, prophylactic surgery,
chemoprevention, and risk avoidance”).
175. Myriad I, 653 F.3d 1329, 1334 (Fed. Cir. 2011), vacated sub nom. Ass’n for
Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 (2012) (mem.),
remanded to 689 F.3d 1303.
176. Myriad Genetics, 132 S. Ct. 1794 (order granting cert., vacating judgment, and
remanding case).
177. See Myriad II, 689 F.3d at 1308 (detailing the remand instructions given by the
Supreme Court).
178. Id. at 1309.
179. Id. at 1333. Specifically, plaintiffs challenged method claims of: U.S. Patent
No. 5,753,411 (filed Nov. 27, 1996), U.S. Patent No. 5,710,001 (filed Jun. 7, 1995),
and U.S. Patent No. 5,709,999 (filed Jun. 7, 1995). Plaintiffs also challenged method
claims one, two, and twenty of U.S. Patent No. 6,033,857 (filed Mar. 20, 1998).
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subgenres: (1) comparing and analyzing methods, and (2)
therapeutic screening methods. 180
Most of Myriad’s method claims involved analyzing and comparing
a patient’s BRCA gene sequence with the “wild-type” sequence to
identify mutations corresponding with a predisposition to breast and
ovarian cancers.181 The comparing and analyzing method claims
were each composed of a single step.182 That step included either
“analyzing” a sequence of a BRCA gene from a patient to check for
certain mutations or “comparing” a patient’s BRCA gene with the
“wild-type” and mutant versions of the BRCA gene.183
The Federal Circuit first explained that a simple comparison or
analysis is an unpatentable mental step.184 Unfortunately for Myriad,
the only real substance to either of its method claims was a simple
comparison.185 The Federal Circuit noted this point stating, “the step
of comparing two DNA sequences is the entire process that is
claimed.”186 Thus these method claims were held unpatentable.187
Myriad, much like Prometheus, attempted to circumvent the
Court’s logic by claiming that its process necessarily incorporated two
transformative steps: (1) extracting DNA from a human sample, and
(2) sequencing the BRCA DNA molecule.188 The Federal Circuit
immediately rejected this characterization because these two
additional steps were not referenced within Myriad’s actual method
claims.189 The court continued that, without these extra steps,
Myriad’s claims were weaker than the claims in Mayo because they
lacked any potentially transformative steps, such as administering a
drug or obtaining a metabolite sample from a patient.190 As such, the
180. Id. at 1334–35.
181. Id. at 1309.
182. Id.
183. Id.
184. See id. at 1334 (relying on Gottschalk v. Benson, 409 U.S. 63, 67 (1972), to
explain that a comparison falls outside the scope of § 101 because it is an
unpatentable mental process, one of “the basic tools of scientific and
technological work”).
185. See id. (explaining that the act of comparing a BRCA sequence from a tumor
and non-tumor sample is “nothing more than the abstract mental steps” required to
compare two different things, thus is an unpatentable mental process).
186. Id. at 1335.
187. See id. at 1334 (rejecting, additionally, the argument that the comparison step
was an application of an abstract idea as part of a process, which is patentable).
188. Id. at 1335; see also supra Part I.E-F (explaining how the patent holder in Mayo
attempted to use the “machine-or-transformation” test to avoid the Supreme Court’s
holding that its claim was a recitation of a law of nature).
189. See Myriad II, 689 F.3d at 1335 (rejecting the argument because the claims
themselves contained no further steps other than performing the comparison and
because “comparing” or “analyzing” does not mean “extracting” or “sequencing”).
190. See id. (comparing the comparison and analysis steps in Myriad’s patent
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Court invalidated Myriad’s sequencing and analysis claims as abstract
mental processes.191
c.

The therapeutic methods

Myriad’s therapeutic method claimed a process of screening
potential cancer therapeutics and comprised of four steps: (1)
growing cells transformed with a mutated BRCA gene, (2) placing
half of these cells in the presence of a compound suspected of being
a cancer therapeutic, (3) keeping the other half of these cells from
such compounds, and (4) comparing the growth rate of both groups
of cells.192 The Federal Circuit began analyzing this claim by looking
at the first step of the claimed process.193 Immediately, the Court
noted that the first step added something significant to the law of
nature.194 The act of transforming cells by introducing a mutant
BRCA gene was a step that resulted in an unnatural manmade cell
with enhanced functionality.195 The court deemed this therapeutic
method claim patentable subject matter because the first step took
the claim beyond simply adding the words “apply it” and, thus,
transformed a law of nature into a patent-eligible application of
the law.196
The Federal Circuit’s opinion teaches two important lessons to
inventors for drafting valid method patents. First, simply “growing”
cells, although a physically transformative step, is probably not
sufficient to render a method claim patentable.197 The key fact in
Myriad was not that the company grew cells, but that the cells were a

to the “administering” and “determining” steps rejected by the Supreme Court
in Mayo).
191. See id. (explaining that the process could be completed by “mere
introspection alone”).
192. See id. at 1336.
193. Id.
194. Id. (comparing the transformed cells to the manmade cells from Chakrabarty
and concluding that this kind of transformation satisfies § 101 patentability
requirements for method claims).
195. See id. (emphasizing that the transforming of cells requires more than simply
“comparing” cells and concluding that the manmade nature of the cells makes them
patent-eligible).
196. See id. (noting that there was patent-eligibility for a novel and nonobvious
manmade cell even if the cell yielded from a well-known and established process or
method). The Federal Circuit limited its holding because the method pertained
only to the specific host cells that were transformed with specific genes, suggesting
that these manmade cells were the key to patentability for this method claim. Id. at
1337.
197. See id. at 1336 (reasoning that “the abstract mental step of looking at two
numbers and ‘comparing’ two host cells’ growth rates” would be insufficient for
purposes of § 101).
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product of human ingenuity, not nature.198 Therefore, purely
physical changes, even if central and necessary for the success of the method,
may not alone be sufficient for patentability.199 Second, if a method
involves or results in a nonobvious, novel product, that method is
likely patentable subject matter under § 101.200 Thus, a diagnostic
method may become patentable if it can tie itself to a novel or
nonobvious product, such as a diagnostic drug or genetic test kit.201
d.

Myriad’s return to the Supreme Court

After the Federal Circuit’s second ruling, the Supreme Court once
again granted Myriad’s petition for certiorari.202 In its recent
decision, the Supreme Court only addressed the patentability of
Myriad’s composition claims for isolated BRCA genes and manmade
cDNA.203 The court expressly noted that it did not consider the
patentability of any method claims.204 Thus, to the extent this
Comment discusses the patentability of methods of genetic diagnostic
testing, the Supreme Court’s recent decision is simply inapplicable.205

198. See id. (“The transformed, man-made nature of the underlying subject matter
in claim 20 makes the claim patent-eligible. The fact that the claim also includes the
steps of determining the cells’ growth rates and comparing growth rates does not
change the fact that the claim is based on a man-made, non-naturally occurring
transformed cell—patent-eligible subject matter.”).
199. See id. (requiring that the claim be a product of man, not of nature).
200. See id. (“By definition, however, performing operations, even known types of
steps, on, or to create, novel, i.e., transformed subject matter is the stuff of which
most process or method invention consists . . . . In situations where the objects or
results of such steps are novel and nonobvious, they should be patent-eligible.”).
201. See, e.g., Optigen, LLC, v. Int’l Genetics, Inc., 777 F. Supp. 2d 390, 403–04
(N.D.N.Y. 2011) (showing a case brought for patent infringement in which there was
no question as to the validity of a compositional claim on a physical genetic
diagnostic test kit).
202. Ass’n for Molecular Pathology v. Myriad Genetics Inc., 133 S. Ct. 694 (2012)
(granting certiorari but limiting the scope of review to only whether human genes
themselves were patentable).
203. See Myriad III, 133 S. Ct. 2107, 2112, 2119 (2013) (emphasizing that the
Supreme Court’s decision does not implicate method patents). See generally Caile
Morris, Ass’n for Molecular Pathology v. Myriad Genetics, Inc., No. 12-398, slip op.
(U.S. June 13, 2013), A M . U. B US . L. R EV . B LOG (Aug. 26, 2013), http://www.aublr
.org/2013/08/assn-for-molecular-pathology-v-myriad-genetics-inc-no-12-398-slip-op-us-june-13-2013-available-at-httpwww-supremecourt-govopinions12pdf12-398_1b7d-pdf
(providing a brief overview of the Supreme Court’s most recent decision).
204. Myriad III, 133 S. Ct. at 2119.
205. Id.
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II. TOGETHER, MAYO AND MYRIAD CATEGORICALLY ELIMINATED
PATENTS FOR METHODS OF DIAGNOSING GENETIC PREDISPOSITIONS TO
ILLNESS.
The Supreme Court’s holding in Mayo and the Federal Circuit’s
holding in Myriad II have likely eliminated genetic diagnostic
methods as patentable subject matter under § 101. This is not to say
that there is no practical way for genetic diagnostic tests to be
protected by patent law. Quite the contrary, companies, such as
Myriad, may still be able to maintain monopolies on diagnostic tests.
So long as a company holds a compositional patent on a method of
implementing the diagnostic test, the overall test may still receive
patent protection.206 Additionally, the Supreme Court has suggested
that a novel method of identifying a mutated gene within a patient
might also be patentable.207 This possibility, however, is outside the
scope of this Comment. Regardless of whether compositional claims
might offer respite for inventors, specific method claims themselves
likely cannot be granted patent protection.
A. Synthesizing a Rule from Mayo and Myriad To Provide a Framework for
Understanding Method Patents for Diagnostic Procedures
1.

The three-step inquiry
Mayo and Myriad, when viewed in the context of prior Supreme
Court precedent, provide a framework for understanding method
patents for diagnostic procedures. Specifically, a test for patentability
may be extrapolated from the Supreme Court’s and Federal Circuit
Court of Appeal’s logic. When determining whether a particular
diagnostic method is patentable subject matter under § 101 the Court
will (1) identify the end purpose of the patented method, and
whether the end purpose entirely preempts a natural law;208 (2) look
at each step of the patented method one-by-one to determine
whether the step is an abstract mental process or whether it adds any
“non-conventional” step to the process;209 and (3) determine whether

206. See infra notes 313–318 and accompanying text.
207. Myriad III, 133 S. Ct. at 2119–20.
208. See, e.g., Parker v. Flook, 437 U.S. 584, 585 (1978) (defining, first, the purpose
of the patent at issueto update an alarm limit).
209. See, e.g., Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289,
1297–98 (2012) (considering individually each step of the methodan
“administering” step, a “wherein” step, and a “determining” stepafter defining the
method’s overall purpose).
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the combination of the steps as a whole transform the process into
something more than the sum of its parts.210
The first step in any method patentability inquiry is to identify the
end purpose of the patent. This principle can be traced back to the
Supreme Court’s reasoning in Benson, Flook, and Diehr. For example,
in Benson the Court’s first step was to identify the purpose of the
patentin that case, the ability to convert signals from binary-coded
decimal form into pure binary form.211 Unfortunately for Benson,
the necessary mathematical algorithm would be completely
preempted because the algorithm involved had no substantial
practical application without using a computer; accordingly, the
patented mathematical formula would, in effect, be a patent on the
algorithm itself.212 Likewise in Flook, the Court first identified the
purpose of the methodupdating an alarm limit.213 The Court
found that, although this purpose seemed narrower than simply
claiming the mathematical formula, it had no relevant limiting
factors in any of its steps other than conventional and well-known
post solution activity.214
The decision in Mayo highlighted the importance of the first step
of this analysis. In Mayo, the Court identified the purpose of
Prometheus’s patent as identifying the optimal level of 6-TG to give a
patient.215 The Court explained that achieving this end was only
made possible by Prometheus’s discovery of the correlation between
6-TG concentration in the blood and ill-effects in a patient.216 This
correlation was the “law of nature” Prometheus attempted to patent;
an identification crucial to the Court’s reasoning.217
The second step of the analysisanalyzing a method claim step-bystepwas essential in Mayo to determine if any of the steps described
210. See, e.g., id. at 1298 (“[T]o consider the three steps as an ordered
combination adds nothing to the laws of nature that is not already present when the
steps are considered separately.” (citing Diamond v. Diehr, 450 U.S. 175, 188
(1981))).
211. See Gottschalk v. Benson, 409 U.S. 63, 64–67 (1972) (beginning the Court’s
analysis by describing how the patent as a whole functioned to convert binary-coded
decimals into pure binary numerals).
212. See id. at 68, 71–72 (explaining that although the method could be carried
out without a computer, any practical use depended on a computer).
213. Flook, 437 U.S. at 586.
214. See id. at 595 (observing that a claimed method is nonstatutory when the
claim is directed to a method of calculating, even if the algorithm is designed for a
specific purpose (quoting In re Richman, 563 F.2d 1026, 1030 (Fed. Cir. 1977))).
215. Mayo, 132 S. Ct. at 1296–97.
216. See id. at 1297 (explaining that “the [cor]relation itself exists in principle
apart from any human action”).
217. See id. (identifying the correlation as the “natural law” that Prometheus
attempted to exploit and advancing to the second prong of the inquiry as to whether
any step in the process added something more to transform that natural law).
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more than just natural law to make the claims patent-eligible.218 This
step of the analysis proved determinative in Myriad, when the Federal
Circuit examined Myriad’s therapeutic method claim.219 The first
step of that method involved a manmade organism, which
immediately elevated the claim above a simple recitation of natural
law.220 Accordingly, a transformation in any step allows for patenteligibility for a method claim when that transformation is both (1)
central to the claim and (2) results or involves a non-routine,
nonobvious product or procedure.221
The third step in the analysis, introduced by the Supreme Court in
Mayo, acts as a failsafe device.222 If the individual steps of a method
patent merely “inform a relevant audience about certain laws of
nature,” and only include “well-understood, routine, conventional
activity already engaged in by the scientific community,” the only way
a claimed method can be patentable is if, when viewed as a whole, it is
more than “the sum of [its] parts.”223 Although such a situation is
theoretically possible, the Court in Mayo provided no examples.224
2.

Reexamining Myriad‘s comparing and analyzing claims
In Myriad, the Federal Circuit was unable to fully apply the
Supreme Court’s step-by-step Mayo analysis to Myriad’s “comparing”
and “analysis” patents because these patents had only one step per
method. Each single-step involved a simple abstract mental process,
making any step-by-step analysis impossible. Therefore, the Federal
Circuit’s logic left open the hypothetical question: what if Myriad
had claimed a process involving (1) extracting DNA from a human
sample, (2) sequencing that sample, and then (3) comparing that sample to
the known “wild-type” and mutant versions of the same gene?225
218. See id. (addressing individually each of the three steps—the “determining”
step, “administering” step, and the “wherein” step—to determine whether the claim
allowed the processes to qualify for a patent).
219. Myriad II, 689 F.3d 1303, 1336 (Fed. Cir. 2012) (explaining that the very first
step of the method was premised on the use of transformed, manmade host cells),
aff’d in part, rev’d in part on other grounds, 133 S. Ct. 2107 (2013).
220. See id. (arguing that performing operationseven operations that involve
known types of stepsto create novel subject matter transforms the nature of the
claim to patent-eligible subject matter).
221. See supra notes 115–141 and accompanying text (detailing the standard by
which the Mayo court considered Prometheus’s method patents).
222. See Mayo, 132 S. Ct. at 1298 (describing this third step as simply instructing
doctors to engage in conventional activity that scientists in the field have already
been engaging in).
223. Id.
224. Id.
225. This kind of claim has already been submitted to the USPTO. See, e.g.,
Biomarker for Successful Aging Without Cognitive Decline, U.S. Patent No.
8,216,787 (filed Apr. 14, 2010).

BERGIN.OFF._TO_PRINTER (DO NOT DELETE)

2013]

TAKE OFF YOUR GENES

11/2/2013 12:20 PM

203

Applying the three-part test identified above, the first step is to
identify the purpose of the method and the law of nature or abstract
process that the method claim is attempting to use.226 According to
the abstracts and specifications of their patents, Myriad’s invention
related to diagnosing a predisposition to breast cancer.227 Much like
Prometheus’s method claims in Mayo, which patented a method in an
attempt to protect the correlation it discovered between certain levels
of 6-TG and drug efficiency, Myriad attempted to protect the
correlation between the presence of the mutant BRCA gene in a
patient and a heightened likelihood of breast and ovarian cancer.228
Thus, like in Mayo, the law of nature being exploited here is
essentially a correlation, which the court has already deemed an
unpatentable abstract principle.229
After identifying the purpose of the method and the law of nature
being utilized, the next step is to determine whether any of the
individual steps of the proposed method add to this law of nature.230
In Mayo, the Supreme Court clarified that a “well-understood,
routine, [or] conventional” step adds “nothing” significant to the
method and is thus insufficient to move the claim from an
unpatentable natural correlation to an application of those
occurrences, which could comprise a patentable claim.231
The first step of the hypothetical Myriad patent is extracting DNA.
In the specification of its patent, Myriad identified several potential
methods for isolating and extracting DNA.232 These methods were

226. See supra notes 208–210 and accompanying text (outlining the three-part test
for diagnostic method patents).
227. See U.S. Patent No. 5,709,999 col.1 l.20–22 (filed Jun. 7, 1995) (“Specifically,
the present invention relates to methods and materials used to isolate and detect a
human breast and ovarian cancer predisposing gene . . . . More specifically, the
invention relates to germline mutations in the BRCA1 gene and their use in the
diagnosis of predisposition to breast and ovarian cancer.”), invalidated by Myriad II,
689 F.3d 1303 (Fed. Cir. 2012), aff’d in part, rev’d in part on other grounds, 133 S. Ct.
2107 (2013).
228. See Myriad II, 689 F.3d at 1315–16 (explaining that the reason the suit against
Myriad was brought in the first place was to stop other practitioners from providing
BRCA diagnostic tests); ‘999 Patent at col.4 l.22–23 (“Identification of a breast cancer
susceptibility locus would permit the early detection of susceptible individuals . . . .”).
229. See generally ‘999 Patent (describing the method as involving screening
suspected BRCA1 mutant alleles, and that the presence of a mutant allele means a
greater susceptibility to breast cancer).
230. Supra text accompanying note 218.
231. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1298
(2012) (requiring significant post-solution activity for a claim to be elevated to be
patentable).
232. ‘999 Patent at col.13 l.4–8 (“This can be determined by testing DNA from
any tissue of the person’s body. Most simply, blood can be drawn and DNA
extracted from the cells of the blood. In addition, prenatal diagnosis can be

BERGIN.OFF._TO_PRINTER (DO NOT DELETE)

204

AMERICAN UNIVERSITY LAW REVIEW

11/2/2013 12:20 PM

[63:173

attributed to publicly available journals and are generally well-known
techniques.233 The Supreme Court’s reasoning in Flook and Diehr
indicate that a transformation, which involves obvious and
conventional procedures or products, is insufficient on its own to
satisfy the § 101 bar.234 Extracting DNA is a conventional step used in
a range of different genetic tests, and therefore, is likely insufficient
to satisfy the § 101 bar.235
Additionally, this step cannot be
considered a “transformation” because as the Court discussed in
Mayo, it could theoretically become irrelevant in the near future
should an entirely new system be developed for identifying a person’s
DNA code.236 For both of these reasons, the Court would likely not
have viewed the hypothetical extraction step as a “transformation.”
The second step in the hypothetical process is sequencing DNA.
Utilized since the beginning of the Human Genome Project, DNA
sequencing is just as banal a step as extracting.237 Given its current
ubiquity in modern scientific inquiry in environments ranging from
criminal enforcement to paternity tests featured on daytime talk shows,
sequencing can almost certainly be considered a conventional step.238
The last step of the inquiry is to determine whether the steps as a
whole add anything to elevate the law of nature to patentable subject
matter.239 In Myriad’s diagnostic claims, there was no transformation
of significant magnitude that was found in its therapeutic claim.240
accomplished by testing fetal cells, placental cells or amniotic cells for mutations
of the BRCA1 gene.”).
233. Id.; see also Myriad III, 133 S. Ct. 2107, 2119 (2013) (“[T]he processes used by
Myriad to isolate DNA . . . were well understood, widely used, and fairly uniform . . .
.” (internal quotation marks omitted)).
234. See supra text accompanying notes 116–136 (examining whether the patented
claims sufficiently add enough to their statements of the correlations as to allow the
processes that they describe to be patent-eligible).
235. See Russell, supra note 1, at 103 (referring to steps such as sequencing and
analyzing as “nothing more than a data-gathering step”).
236. Mayo, 132 S. Ct. at 1303.
237. See SUMMARY REPORT, supra note 2, at 1 (explaining that the analysis begins
“with the task of ordering overlapping recombinant DNA fragments obtained from
purified human chromosomes”); see also ‘999 Patent (explaining several different
known methods to identify and screen for specific DNA sequences); Kanigel, supra
note 2 (explaining that the ability to sequence DNA began the genomic revolution).
238. See Kanigel, supra note 2, (noting that once a physical genome map is
completed, companies can sell information on DNA bases to be used in such
instances); see also Russell, supra note 1, at 103 (explaining that “data-gathering” steps
are insignificant).
239. See supra text accompanying notes 182–184 (describing the holding that
comparing and analyzing a patient’s gene sequence with the “wild-type” sequence is
unpatentable).
240. Compare Myriad II, 689 F.3d 1303, 1335 (Fed. Cir. 2012) (asserting that Myriad
attempts to read into its claims the additional steps of “extracting” and “sequencing,”
but the use of these terms does not), aff’d in part, rev’d in part on other grounds, 133 S.
Ct. 2107 (2013), with id. (incorporating the creation of novel manmade cells within
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Additionally, similar to the patent in Mayo, the hypothetical Myriad
patent can be summed up as (1) measuring, by any method, the
current levels of the relevant metabolite, and (2) applying particular
laws of nature to understand that the presence of a mutation
correlates to a heightened susceptibility to breast and ovarian
cancers.241 It is highly unlikely that a court would find that this
method, taken as a whole, added anything to the basic “law of
nature.” Even with terms such as sequencing and analyzing, the steps
add nothing, either by themselves or taken together, and therefore
cannot overcome the § 101 statutory bar. Thus these patents would
likely be invalidated if challenged.
3.

Reexamining Myriad’s therapeutic claims
In light of the Supreme Court’s decision to uphold Myriad’s
therapeutic patent claims, it may seem unreasonable to suggest that
together Mayo and Myriad categorically eliminate diagnostic method
patents; however, once the Mayo/Myriad test is applied to Myriad’s
therapeutic patents the distinction becomes clear.
Applying the three-part Mayo/Myriad test, the first step is to identify
the purpose of the method and the law of nature or abstract process
that the method claim is attempting to use.242 According to the
patent specification, the purpose of the therapeutic claim was to
provide “methods of screening drugs for cancer therapy to identify
suitable drugs for restoring BRCA1 gene product function.”243 Nevertheless,
this claim has a different purpose than Myriad’s other claims; the
purpose of the therapeutic claim is to identify a suitable drug, not a
predisposition to cancer in a patient.244 This is unlike a diagnostic
patent, which would be used to detect the presence of or
predisposition to cancer in a patient.245 To identify these drugs,
Myriad’s therapeutic method claims instruct the user to “(1) grow[]
host cells transformed with an altered BRCA1 gene in the presence or
absence of a potential cancer therapeutic, (2) determin[e] the
growth rate of the host cells with or without the potential therapeutic,
and (3) compar[e] the growth rate of the host cells.”246 Myriad
the method, or imply any “processing” of a human sample).
241. Mayo, 132 S. Ct. at 1299.
242. See supra text accompanying notes 208–210 (identifying the three steps of the test).
243. U.S. Patent No. 5,747,282 (filed June 7, 1995) (emphasis added).
244. See id. (relating the invention to the screening of drugs for cancer therapy).
245. See id. (describing different therapies associated with cancers caused by a
mutation in the BRCA1 gene, such as gene therapy, protein replacement therapy
and protein mimetics).
246. Myriad II, 689 F.3d 1303, 1336 (Fed. Cir. 2012), aff’d in part, rev’d in part on
other grounds, 133 S. Ct. 2107 (2013).
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further claimed that the law of nature being used in its method was
the correlation between growth rates and the effectiveness of a
potential cancer therapeutic.247
After identifying the purpose of the method and the law of nature
being utilized, the next step is to determine whether any of the steps
of the proposed method add a non-conventional element to this law
of nature.248 In its decision, the Federal Circuit immediately saw that
the first step of the patent—growing transformed manmade cells—
added a significant non-conventional step to the method.249 The
court explained that unlike in Myriad’s genetic diagnostic claims, the
results of such therapeutic steps are novel and nonobvious, and thus,
were patent-eligible.250 Myriad’s therapeutic claim did not just exploit
and preempt a law of nature, which would lead to ineligibility,
because it involved incorporating a novel manmade organism to use
during experimentation.251 Because the claim did not cover all
methods of determining the therapeutic effect of a compound, and
instead was just tied to a specific type of therapeutic, the claim
survived § 101.252
B. Applying the Mayo/Myriad Test to Claims in Method Patents
Testing for a genetic predisposition is essentially testing for the
presence of a particular gene that correlates strongly with a
predisposition to cancer. Accordingly, any genetic test is an attempt
to exploit this correlation, much like the patent in Mayo. In Mayo,
the Supreme Court held that to be patentable, methods attempting
to exploit a correlation must include a non-frivolous, nonconventional step.253 Myriad met this standard in its therapeutic
claim by requiring the use of a novel, transformed host cell.254
247. See id. at 1335–36 (suggesting that a correlation between slower growth rate
in the presence of a potential therapeutic and the compound being a cancer
therapeutic does not preempt a scientific principle).
248. See supra text accompanying notes 184–187 (referencing the holding that a
simple comparison or analysis does not add anything new, and therefore is an
unpatentable step).
249. See Myriad II, 689 F.3d at 1336 (emphasizing that Myriad’s therapeutic claim
employs transformative steps that “are a product of man, not of nature”).
250. Id.
251. See id. (including “the steps of determining the cells’ growth rates and
comparing growth rates [in the larger claim] does not change the fact that the claim
is based on a man-made, non-naturally occurring transformed cell—patent-eligible
subject matter”).
252. Id. at 1336–37.
253. Id. at 1336.
254. See id. at 1336–37 (hinging patentability on specific host cells transforming
with specific genes and growing “in the presence or absence of a specific type of
therapeutic”).
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Nevertheless, a patentee making a claim for genetic diagnostic tests
would likely be unable to add such a novel approach to the patent’s
steps because once a disease allele has been identified it is relatively
easy to identify its presence in a patient.255 Additionally, there are
many readily available tools a researcher can employ to determine
whether a disease allele is present.256 Applying the rationale from
Mayo and Myriad to currently held patents for genetic diagnostic tests
illustrates the difficulty associated with trying to instill novelty into a
correlative genetic diagnostic test.
Patents granted before Myriad
Many patents granted by the USPTO before the decision in Myriad
tend to follow the same “analyze” and “compare” formula that was
invalidated in Myriad. United States Patent No. 7,479,380257 and U.S.
Patent No. 8,211,638258 provide examples for applying the
Mayo/Myriad test to existing patents.259 Both the ‘380 Patent and the
‘638 Patent disclosed a method for determining predispositions for
disease and both methods were composed of two steps: (1) detecting
a mutation in the patient, and (2) determining whether the patient
had a disease predisposition based on the presence or absence of the
mutation.260 These kinds of method claims are likely invalidated by
the current three-step test for method patentability.
Walking through the three-step test, courts must first identify the
purpose of the method claim.261 The purpose of the claim is used to
identify a predisposition to a disease, or a genetic disease condition
itself.262 To accomplish this task, the inventor relies on a correlation
1.

255. See Verbeure, supra note 3, at 15 (explaining that the development of genebased diagnostic testing does not require a large investment); see also Russell, supra
note 1, at 103 (explaining that the process of identifying known mutations is a simple
data gathering step).
256. See Verbeure, supra note 3, at 15 (among the various tests that are currently
available, over a thousand genetic diseases can be diagnosed); see also Myriad III, 133
S. Ct. 2107, 2119 (2013) (explaining that there are processes which may be used to
isolate DNA which are “well understood, widely used, and fairly uniform”).
257. Method for Assessing Behavioral Predisposition, U.S. Patent No. 7,479,380
(filed July 11, 2003).
258. Genetic Polymorphisms Associated with Liver Fibrosis, Method of Detection
and Uses Thereof, U.S. Patent. No. 8,211,638 (filed Apr. 29, 2010).
259. As seen in the Mayo and Myriad tests, both of these patents rely on the
existence of certain environmental specificities to find a connection between
possessing a gene and being a risk for a disorder. See generally ‘380 Patent (providing
the patent is for determining behavioral predisposition); ‘638 Patent (stating the
patent as a method for associating a specific polymorphism with liver fibrosis).
260. See ‘380 Patent; ‘638 Patent.
261. Supra text accompanying notes 211–217.
262. See ‘380 Patent at [57] (“The present invention relates to diagnostic methods
for assessing predisposition of a subject to a mental disorder phenotype . . . .”); ‘638
Patent at [57] (“The present invention is in the field of fibrosis diagnosis and therapy
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between the existence of a genetic mutation, and the disease
phenotype.263 As seen in Mayo, when a method’s purpose depends
upon a natural correlation, the steps are then considered separately
and must add something significant to the law of nature.264
The two steps in the ‘638 Patent and ‘380 Patent mirror the failed
method claims from Myriad. Much like in Myriad, the “determining”
and “comparing” steps only inform a person using these methods of a
naturally occurring correlation and suggest consideration of this
correlation when determining an increased likelihood of disease.265
Additionally, because the “determining” step necessitates other steps,
such as obtaining a sample from the patient or profiling a subject’s
allele via a nucleic acid microarray, this step is not enough for
patentability for two reasons. First, because these steps were not
claimed steps in the first place;266 and, second, because even if these
steps were claimed within the overall method claim, they would likely
amount to banal pre-solution activity.267
The procedures for
obtaining genetic samples from patients or sequencing those samples
are conventional, well-known steps.268 Indeed, those steps are so
ordinary that the claimed methods assume that a person with
ordinary skill in the art already knows the requirements for
“determining” a mutation.269
and in particular liver fibrosis diagnosis and therapy . . . .”).
263. See ‘380 Patent (relating a mental disorder phenotype and an at-risk allele of
a brain function gene); ‘638 Patent (relating particular nucleic acid molecules and
methods of using the nucleic acid and protein).
264. See supra text accompanying notes 184–87 (explaining that mental steps that
simply involve making comparisons add nothing to natural law).
265. See Myriad II, 689 F.3d 1303, 1335 (Fed. Cir. 2012) (noting that Myriad’s
method patents contained only “comparing” and “analyzing” steps which were not
transformative), aff’d in part, rev’d in part on other grounds, 133 S. Ct. 2107 (2013).
266. See id. (explaining that the extracting and sequencing steps were not
mentioned in the claim, and thus would not be considered for validity).
267. See supra text accompanying notes 142–44 (explaining that administering
tests will not be considered transformative).
268. Id.; see Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702
F. Supp. 2d 181, 200 (S.D.N.Y. 2010), (noting that the techniques used for
sequencing are well-known and used daily by scientists in the field of genetics), aff’d
in part, rev’d in part, Myriad I, 653 F.3d 1329, 1334 (Fed. Cir. 2011), vacated sub nom.
Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 (2012)
(mem.), remanded to 689 F.3d 1303, aff’d in part, rev’d in part on other grounds, 133 S. Ct.
2107; see also Myriad II, 689 F.3d at 1335 (“extracting” and “sequencing”—i.e.,
obtaining a sample and testing it—is insufficient for patentability).
269. See U.S. Patent No. 7,479,380 col.2 l.55–58 (filed July 11, 2003) (the method
steps include “determining whether the subject carries a two- or three-repeat allele of
a variable . . . and concluding that the subject is predisposed to the phenotype if the
subject carries the two- or three-repeat allele”); U.S. Patent No. 8,211,638 (filed Apr.
29, 2010) (detailing a method comprising of testing a human’s nucleic acid and
correlating the presence or absence of an allele at certain positions on the
nucleotide); see also ‘380 Patent col.7 l.9 (explaining in the specification that a “wide
range of profiling tests exist” which a physician should already be aware of).
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Other patents granted before the decision in Myriad included “presolution” steps such as obtaining a sample from a patient270 or
running PCR amplifications.271 These steps refer to unpatented,
routine procedures that amount to nothing more than common datagathering steps.272 Transformations that do not involve or produce
nonobvious or novel material are insufficient to elevate a method
claim above the § 101 bar.273 Therefore, patents that were approved
before Mayo and Myriad should now be considered unpatentable
because they do not add anything novel to the process.
Patents granted after Myriad
Since the Federal Circuit decided Myriad II in August 2012, several
patent applications for genetic diagnostic tests have cleared the
USPTO.274 The method claims that have passed through the USPTO
can be divided into three general groups: (1) those that have added
terms and unnecessary extra steps to their core method claim, (2)
those that are phrased in such a way so as to incorporate physical
biological structures in their claims, and (3) those that capture the
method claim inside a compositional claim. This section discusses
these claims and argues that if challenged, a court would likely
invalidate them in light of the Mayo/Myriad test.

2.

270. See, e.g., U.S. Patent No. 7,521,190 col.175 l.39–40 (filed Mar. 2, 2007) (“A
method for detecting in an individual the presence or absence of a mutant PKD gene
comprising: (a) obtaining a nucleic acid sample . . . and (b) detecting the presence
or absence of one or more mutations . . . .”).
271. See, e.g., U.S. Patent No. 7,638,308 col.13 l.56 (filed Jul. 6, 2005) (describing
the method for disease diagnosis as “running PCR amplification . . . and DNA typing
the resulting PCR amplification products”); U.S. Patent No. 8,221,979 col.139 l.2–5
(filed Nov. 16, 2011) (“A method for diagnosing Noonan syndrome . . . comprising
amplifying all or part of a . . . (SOS1) nucleic acid molecule . . . and detecting a
mutation in the SOS1 nucleic acid molecule . . . .”). PCR stands for Polymerase
Chain Reaction, and is a method of replicating DNA. Karmin T. MacKnight, The
Polymerase Chain Reaction (PCR): The Second Generation of DNA Method Analysis Takes
Hold, 9 SANTA CLARA COMPUTER & HIGH TECH L.J. 287 304–08 (1993). Generally
speaking PCR is a “DNA photocopy machine,” which makes thousands of DNA
copies from one sample. Id. This process allows researchers to identify the presence
of specific genes in a given DNA sample. See generally id. (explaining exactly how PCR
is used).
272. See Russell, supra note 1, at 102 (suggesting that data collecting steps are
generally meaningless post-solution activities).
273. See supra text accompanying notes 184–87 (discussing the Federal Circuit’s
rejection of method claims involving only mental steps, asserting “the step of
comparing two DNA sequences is the entire process that is claimed”).
274. See, e.g., Method of Profiling Gene Expression in a Subject Having
Alzheimer’s Disease, U.S. Patent No. 8,257,922 (filed Apr. 9, 2010); Methods For
Predicting & Treating Tumors Resistant to Drug, Immunotherapy & Radiation, U.S.
Patent No. 8,257,928 (filed Sep. 7, 2011).
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Escaping Mayo and Myriad: throwing science at the wall

Generally speaking, claims for genetic diagnostic patents have
three basic steps: (1) obtaining a DNA sample from a patient,
thereby establishing a providing, collecting, or obtaining step, (2)
sequencing that DNA sample, and (3) comparing the patient’s DNA
sequence to other known wild-type and mutant strands to determine
if the patient has a mutation.275
To escape the result of Mayo and Myriad, some patents have
attempted to add several steps and terms to their diagnostic method
claims. A prime example is U.S. Patent No. 8,236,500.276 This patent
claims
A method, comprising: a) providing; i) an individual suspected of
having a predisposition to schizophrenia; ii) a nucleic acid derived
from said individual, wherein said nucleic acid comprises an alpha7
nicotinic acid receptor regulatory allele; b) detecting at least one
polymorphism within said alpha7 regulatory allele, wherein said
polymorphism comprises −1831 C/A of SEQ ID NO: 181; and c)
correlating the presence of said at least one polymorphism with a
predisposition to schizophrenia.277

This method can be unpacked into the three basic steps for genetic
testing: (1) taking a particular DNA sample from a patient, (2)
determining whether the gene is the “wild-type” or mutant version,
and (3) analyzing whether the person likely has a predisposition to
schizophrenia if the gene is mutated.278 However, when applying the
Mayo/Myriad test, it becomes clear that adding extra terms or steps
cannot raise a correlative test above the § 101 bar.
In determining whether or not the ‘500 Patent is a valid method
claim under § 101 pursuant to the Mayo/Myriad test, the purpose of
the claim and the law of nature at use must first be identified.279
275. See, e.g., U.S. Patent No. 8,236,500 (filed May 29, 2009) (listing the providing,
detecting, and correlating steps). Patenting genetic diagnostic methods has become
more difficult in light of recent Supreme Court decisions. See Russell, supra note 1,
at 92 (explaining the difficulty inherent in diagnostic patents because they need to
show a claim for a fundamental principle rather than a series of steps).
276. Promoter Variants of the Alpha-7 Nicotinic Acetylcholine Receptor, U.S.
Patent No. 8,236,500 (filed May 29, 2009).
277. Id. at col.189 l.1–14 (emphasis added).
278. Id. Viewed this way, a pattern for genetic diagnostic tests begins to emerge
that may be unavoidable. Compare id. (exemplifying the three-step process of (1)
providing, (2) detecting, and (3) correlating), with Mayo Collaborative Servs. v.
Prometheus Labs., Inc. 132 S. Ct. 1289, 1303 (2012) (explaining the three steps of
the Mayo patent), supra text accompanying notes 239–41 (listing the steps of the
hypothetical Myriad patents), and supra text accompanying notes 259–60 (detailing
the steps in the patents granted before Myriad, which passed the § 101 bar because
they added something new or novel to the method).
279. See supra text accompanying notes 242–44 (pointing out that the purpose of
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Here, the stated purpose is to diagnose a predisposition to
schizophrenia, and the law of nature at issue is a correlation between
a mutant gene and the disease condition.280 The next step is to
analyze the method steps one-by-one to determine if they add
anything significant to the law of nature.281
The patent claim’s first step involves obtaining a sample from a
patient. This step is very similar to the first proposed step in the
hypothetical Myriad patent.282 Simply obtaining a sample has
generally been held insufficient for method patentability.283 The
second step of the ‘500 Patent is to detect at least one
polymorphism.284 In effect, this step is identical to the Myriad step of
“analyzing” a particular gene for a mutation.285 Moreover, in
PerkinElmer, the Federal Circuit made clear that a “measuring” step by
itself is insufficient to raise a claim to patentability.286 Here, there is
no specific, novel, or unique method of “detecting” required; the
patent simply instructs the user to somehow detect the presence of a
mutation.287 Thus, this step can be discarded as an “abstract mental
process” that could be completed through “mere inspection alone.”288
The final step in the ‘500 patent is correlating the presence of a
mutant gene with a predisposition to schizophrenia,289 which is
clearly the recitation of the “law of nature.”290
Myriad’s claim had a different purpose than its other claims, and thus the method
did not pass the § 101 bar).
280. ‘500 Patent; see, e.g., Myriad II, 689 F.3d 1303, 1314 (Fed. Cir. 2012)
(describing the correlation between mutations in certain genes and breast cancer),
aff’d in part, rev’d in part on other grounds, 133 S. Ct. 2107 (2013).
281. See supra text accompanying notes 249–52 (clarifying that the addition of
something significant to the laws of nature includes steps that are novel and
nonobvious, such as incorporating a man-made organism into experimentation).
282. See supra text accompanying notes 232–33 (stating that the first step of the
hypothetical Myriad patent is extracting).
283. See, e.g., Mayo, 132 S. Ct. at 1303 (explaining that taking blood from a patient
was not a transformation and could not raise the method to the required level of
patentability); see also Russell, supra note 1, at 102 (suggesting that data gathering
steps, such as collecting samples, “can also fairly be characterized as insignificant
extra-solution activity.”).
284. See generally ‘500 Patent (allowing the user to detect, by any method, the
presence of the polymorphism and explaining several different methods of detection).
285. See Myriad II, 689 F.3d at 1334 (holding that analyzing two gene sequences
falls outside the scope of § 101 because the patents claim only abstract mental
processes).
286. See PerkinElmer, Inc. v. Intema, Ltd., 496 F. App’x 65, 71 (Fed. Cir. 2012)
(holding that measuring steps are insufficient to make claims patent-eligible because
the step simply directs users to measure screening markers, but the users can still use
any method they wish), cert. denied, No. 12-1372, 2013 WL 2155734 (Oct. 7, 2013).
287. See ‘500 Patent (demonstrating several ways to detect a polymorphism).
288. See Myriad II, 689 F.3d at 1335 (differentiating Myriad’s claim from any “Mayolike” transformative step because Myriad’s claim involves abstract mental processes).
289. ‘500 Patent at col.3–4 l.43–3.
290. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1297
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This patent’s steps add nothing unconventional or novel to the
overall process, and the steps certainly do not come close to the
“administering” and “determining” steps that the court concluded to
be transformative in Myriad’s therapeutic claims.291 Thus, the
method is nothing more than an attempt to monopolize the
correlation between a particular genetic mutation and a
predisposition to a disease condition. If challenged, the ‘500 Patent
should be invalidated under the Mayo/Myriad test.
b.

Escaping Mayo and Myriad: incorporating physical structures

In the Federal Circuit’s decision in Myriad, the company attempted
to argue that the “sequencing” method claim referred to the
manipulation of the physical DNA molecule itself, not simply to the
information held within the molecule’s structure.292 The Federal
Circuit disagreed and held that the patent only claimed the abstract
process of comparing two sequences; not the physical manipulation
of biological structures.293 Some diagnostic patents granted by the
USPTO since the Federal Circuit decided Myriad incorporate the
physical manipulations of biological structures in their method
claims.294
A good example of this incorporation phenomenon can be found
in U.S. Patent No. 8,263,337295 that discloses another method for
determining a genetic disposition to schizophrenia. Unlike in the
Myriad patent, the ‘337 Patent explicitly describes the targeted
sequence and even the targeted polymorphism as the difference
between the inclusion of an “A” allele or a “G” allele at nucleotide
polymorphism rs135667, which correlates with a predisposition to
schizophrenia, and not just the targeted gene.296
Using the

(2012) (identifying the correlation in Prometheus’s claim as a natural law and thus
the claim was unpatentable because it simply “inform[s] a relevant audience about
certain laws of nature” and merely adds “additional steps consist[ing] of wellunderstood, routine, conventional activity” is invalid under § 101).
291. See Myriad II, 689 F.3d at 1335 (explaining that the therapeutic claim passed
the § 101 bar because it involved the creation of novel manmade cells, which were
central to the purpose of the process involved).
292. See id. (adding that the claims Myriad defended were indistinguishable from
the claims that the Supreme Court invalidated under § 101 in Mayo).
293. See id. (“[T]he claims only recite mental steps, not the structure of physical
DNA molecules.”).
294. See, e.g., U.S. Patent No. 8,323,906 col.4 l.47–55 (filed Dec. 17, 2008)
(describing use of a specific nucleotide sequence to determine host expression).
295. Genetic Markers of Schizophrenia, U.S. Patent No. 8,263,337 (filed Oct. 27,
2011).
296. Id. at col.44 l.23–35.
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Mayo/Myriad three-step test provides guidance as to whether this
specificity raises the method above the § 101 bar.297
The first step is simple; the purpose of the patent is to correlate a
genetic anomaly with a predisposition of schizophrenia.298 Next, each
step of the method must be considered individually.299 The first step
of the ‘337 Patent involves determining whether a particular gene
(the CERK haplotype) is present within the patient.300 Much like the
determining steps in Mayo or PerkinElmer, this step does not explain
how to determine whether this anomaly exists, but leaves that up to
the user.301 In both Mayo and PerkinElmer this kind of discretionary
determining step was insufficient to meet the § 101 bar.302
The second step of the ‘337 Patent is a “wherein” clause, which
states the exact polymorphisms that correspond to a predisposition to
schizophrenia.303 The patent relies on the correlation between the
presence of a polymorphism and a predisposition to schizophrenia.304
Although this patent identifies the specific nucleotide to be
examined, it still remains an abstract idea—a comparison that could
be accomplished by mere introspection alone.305 Providing greater
specificity cannot transform the nature of the method.306 Here, the
297. See supra text accompanying notes 231–35 (explaining that because extracting
DNA is such a commonly used step in a wide array of genetic tests, it is insufficient to
satisfy the § 101 bar).
298. ‘337 Patent col.44 l. 23–35.
299. See supra text accompanying notes 237–38 (illustrating that this step applied
to the first step of the hypothetical patent in Myriad of extracting DNA).
300. ‘337 Patent col.44 l.34–39.
Whether the particular gene is present
determines if the subject has an increased risk of developing schizophrenia. Id.
col.44–45 l.63–3.
301. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1297
(2012) (describing Mayo’s “determining step” as alerting the doctor to determine
the level of the relevant metabolites in the blood, using whatever process he or she
wishes); PerkinElmer, Inc. v. Intema Ltd., 496 F. App’x 65, 71 (Fed. Cir. 2012)
(requiring the “ineligible mental step” of “comparing” measurements with data on
affected pregnancies in order to determine the risk of fetal Down’s syndrome), cert.
denied, No. 12-1372, 2013 WL 2155734 (Oct. 7, 2013).
302. See Mayo, 132 S. Ct. at 1298 (explaining that using an unpatented natural
correlation technique was insufficient for patent eligibility under § 101); PerkinElmer,
496 F. App’x at 71 (comparing the claim to the one in Mayo, which amounted to a
mere “suggestion” that a doctor take a mental step and included no requirement
that a doctor act on the calculated risk, thus making both claims ineligible for
patents under § 101).
303. ‘337 Patent col.44 l.36–40.
304. Id. at col.2 l.15.
305. See Myriad II, 689 F.3d 1303, 1335 (Fed. Cir. 2012) (explaining that narrowing
the claim to a specific genetic region was insufficient because the key still remained
the comparison, an abstract mental process), aff’d in part, rev’d in part on other grounds,
133 S. Ct. 2107 (2013).
306. Prometheus could not escape the § 101 bar even though it identified the
specific biological structure required for its correlation, 6-TG, so it seems unlikely
that genetic diagnostics would be able to escape § 101 this way. See Mayo, 132 S. Ct. at
1294 (reiterating the Court’s instructions that to transform an unpatentable law of
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two different structures are still simply being compared, which is an
abstract mental process.307 It does not matter how specifically
these structures are described; the key lies in the comparison, not
their structures.308
The final step is to consider the method as a whole, and as a whole,
’337 offers nothing beyond the correlation between a particular
genetic mutation and a predisposition to disease.309 Additionally,
there is no non-frivolous or non-traditional transformation anywhere
in this patent.310 While the inventor may argue that transformations
must occur during the “determination” step, the Supreme Court’s
decision in Mayo and the Federal Circuit’s decision in PerkinElmer
demonstrate that a measuring or determination step must include
some novel, nonobvious procedure to rise above the § 101 bar.311
Incorporating biological structures into the method claim of a
genetic diagnostic test should not raise a patent to pass the § 101
statutory bar. The key inquiry in these method claims does not
concern the structure of the genes or the specific locus of a relevant
sequence, but rather the fact that the very presence of a mutation
statistically correlates with a disease condition.312 Thus, although
these kinds of patents identify specific biological structures, because
the process remains identical to other genetic diagnostic tests they
cannot pass the Mayo/Myriad three-part test.

nature into something patent-eligible, restating the law of nature and adding the
words “apply it” is not enough).
307. See id. at 1293 (explaining that the term “analyzing,” when used to describe
the mental process of comparing two different things, is nothing more than an
“abstract intellectual concept[]” that is not patentable).
308. See id. at 1294 (emphasizing that the method claimed must demonstrate
additional elements (or a combination of elements) to ensure that the patent
involves more than ubiquitous activity performed by experts in the field or just a
patent upon the natural law itself).
309. See supra text accompanying notes 184–87 (noting that comparison or
analysis is not patentable).
310. See supra text accompanying notes 142–57 (explaining that to be relevant a
transformation within a method claim must involve a novel product or step, and
must be central to the actual purpose of the method).
311. See Mayo, 132 S. Ct. at 1303–04 (correcting the government’s claim that
anything beyond stating a new law of nature is patentable by showing precedent
requires something nonobvious or novel); PerkinElmer, Inc. v. Intema, Ltd., 496 F.
App’x 65, 71 (Fed. Cir. 2012) (explaining that obvious changes in measuring steps
are insufficient to make a law of nature patent-eligible), cert. denied, No. 12-1372,
2013 WL 2155734 (Oct. 7, 2013).
312. Genetic Markers of Schizophrenia, U.S. Patent No. 8,263,337 col.44 l.23–35
(filed Oct. 27, 2011) (explaining that an individual will have an “increased risk of
schizophrenia,” if they have a certain mutation in his CERK haplotype).
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Escaping Mayo and Myriad: reliance on compositional claims

Despite the challenges, there is a way for a method of genetic
diagnostic testing to gain patent protection. A certain genetic illness
may be successfully patented if the method claim is captured by a
compositional claim.313 An inventor may easily obtain a patent on a
diagnostic test kit or on an eligible diagnostic drug.314 For example,
an inventor may manufacture a test kit for international
distribution.315 This test kit would be sold to physicians and allow
them a simple way to test for genetic predisposition to a disease, such
as cystic fibrosis.316 Alternatively, this test kit could also be sold
directly to consumers for testing at home. Either way, the test kit
itself might be eligible for a patent on its compositional claim.317
These compositional patents may provide protection for the genetic
diagnostic method as a whole; however, it is not a patent on the
genetic diagnostic method itself. These compositional patents may
simply serve to preempt others from using the diagnostic test kit, and
therefore the methods employed by the test kit.318
CONCLUSION
While the patent world was fixated on Myriad because of its
controversial holdings on patents for isolated DNA fragments, the
case’s holding on diagnostic method claims was largely ignored.
When combined with the Supreme Court’s previous ruling in Mayo,
Myriad’s holding may very well require interpretation of 35 U.S.C.
313. See Nicholas J. Landau, The Practical Lessons of Myriad, LAW360 (Sept. 4, 2012,
11:56 AM), www.law360.com/articles/374258/print?section=appellate (advising that
after the Myriad decision, inventors may wish to rely more heavily on compositional
claims instead of method claims to maintain patent protection on diagnostic tests);
supra text accompanying notes 177–73 (explaining that Myriad’s claimed
compositional patents on BRCA1 and BRCA2 were quite helpful in identifying a
patient’s predisposition to breast and ovarian cancers).
314. See Christopher M. Holman, Learning from Litigation: What Can Lawsuits Teach
Us About the Role of Human Gene Patents in Research and Innovation?, 18 KAN. J.L. & PUB.
POL’Y 215, 248 (2009) (predicting an increase of genetic diagnostic testing litigation
due to the rising popularity and prevalence of personalized medicine). But see
Schilling, supra note 8, at 760 (explaining that there are two kinds of tests for
diagnosing genetic predispositions, ones which occur in a laboratory without a kit—
and therefore, ostensibly outside the realm of patent protection—and ones that
customers can take at home with a kit).
315. Schilling, supra note 8, at 760.
316. Id. at 760; Lauren B. Solberg, Over the Counter but Under the Radar: Direct to
Consumer Genetic Tests and FDA Regulation of Medical Devices 11 VAN J. ENT. & TECH. L.
711, 717–18 (2009).
317. Schilling, supra note 8, at 760.
318. See, e.g., Optigen, LLC, v. Int’l Genetics, Inc., 777 F. Supp. 2d 390, 404–05
(N.D.N.Y. 2011) (illustrating an instance in a patent infringement case where it was
undisputed that the defendant was aware of the plaintiff’s patents).
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§ 101 in such a way as to foretell the end of patent protection for
genetic diagnostic tests.
Section 101 of the United States Patent Act prohibits any patent
that attempts to claim a law of nature, natural phenomena, or
abstract idea.319 Applying these exceptions can be very difficult when
assessing the patentability of method claims and especially difficult
when considering diagnostic method claims.320 The Supreme Court
and the Federal Circuit have laid the foundation for understanding
method patents in three phases. First, in Benson, Flook, and Diehr, the
courts explained that to be patentable subject matter, a method claim
could not wholly preempt a natural law, and meaningless postsolution activity could not raise a method to patentability. Then, in
Bilski, the Supreme Court rejected the “machine-or-transformation”
test as a determinative factor in patentability. Finally, in Metabolite
and Classen, the courts determined that transformations were still
useful clues to deterring patentability for methods if they were
central to the claims and involved a novel or nonobvious
product.321 These cases set the framework for Mayo and Myriad,
which created a foundation for understanding the patentability of
genetic diagnostic tests.
Together Mayo and Myriad established a three-part test for
determining diagnostic method patentability: (1) identify the end
purpose of the patented method and whether that end purpose
entirely preempts a natural law; (2) look at each step of the method
to determine whether a step is an abstract mental process or adds any
“non-conventional” element to the process; and (3) determine
whether the combination of the individual steps as a whole
transforms the process into something more than the sum of its parts.
Furthermore, the transformation might raise a method claim to the
level of patentability if the transformation is central to the process
and involves a novel or nonobvious process.
Applying this test to patents, granted before and after Myriad was
decided, demonstrates that genetic diagnostic patents categorically
fail the three-part test. Neither incorporating physical biological
structures nor incorporating a longer list of enumerated steps can
raise a genetic test to the level of patentability because a genetic test
is, at its core, simply a correlation.

319. 35 U.S.C. § 101 (2006); see also Diamond v. Diehr, 450 U.S. 175, 185 (1981)
(explaining the three statutory exclusions to the United States Patent Act).
320. Russell, supra note 1, at 86.
321. Supra text accompanying notes 209–24.
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New correlations between genes and disease conditions are being
made rapidly as science progresses further into the era of
personalized medicine. For better or worse, the Mayo/Myriad
decisions, which likely strip genetic diagnostic tests of their
patentability, ensure that such tests are not monopolized, remain
available to all, and are held exclusively by none.

